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Abstract
After injury, wound healing is a complex sequential cascade of events essential for the
proper recovery of the wound without the scar formation. Nitric oxide (NO) is a small,
endogenous free-radical gas with antimicrobial, vasodilating and growth factor stimulating
properties. NO has wide biomedical application especially in wound healing however, its
usability is hindered due its administration problem as it is highly unstable.
In this work, poly (l-lactic acid) microparticles encapsulated with NO donor S-nitroso-Nacetyl-D-penicillamine (SNAP) were prepared using water-in-oil-water double emulsion
solvent evaporation method for controlled delivery for NO at the specific site. The NO
release from SNAP-PLLA microparticles prepared at two different stirring speeds (500 and
2500 RPM) was evaluated using three main SNAP decomposition triggers i.e. light, copper
and ascorbic acid. The light controlled on and off mechanism of nitric oxide release from
the microparticles at different intensities was demonstrated that can be used to control the
amount of NO release depending on the need. An average total NO release of 6.11 ± 1.71
x10-08 for 9 hrs. and 8.43 ± 2.92 x10-08 for 13 hrs. was observed from microparticle(500) and
microparticle(2500) respectively on exposure to light, copper (II) and ascorbate. Furthermore,
these SNAP-PLLA microparticles were embedded into thermosensitive chitosan-agarose
hydrogel to form microparticle-hydrogel composite. These composites have demonstrated
NO release on exposure to light. An ascorbic acid chitosan-agarose hydrogel composite
system was also used to evaluate the NO release in the presence of only ascorbic acid from
the microparticle hydrogel composite. A significant difference in average total NO release
from both microparticles as well as microparticle-hydrogel composite was observed
because of varying size parameter. These findings suggest that these microparticle as well
as microparticle-hydrogel composite formulations may be useful for wound site
administration of nitric oxide to accelerate wound healing process delayed due to
dysfunction in endogenous NO production caused by pathological infection.

xii

1 Introduction
Millions of people suffer from acute and chronic wounds around the world annually whose
treatments result in major health problems, economic loss, stress, and decreased quality
of life of the patient,(1, 2). At least 1% of the population from developed countries will
suffer complex chronic wounds during their lifetime and in United States alone more than
6.5 million people suffer from complex wounds (3), costing about $10 billion are spent per
year managing these wounds. The global wound care market is estimated to reach over
$22 billion (US) per year by the year 2020 (1). According to a study, wound infection is
responsible for 77% of the surgical deaths (4). The relative risk of death in surgical patients
with wound infection is 2.2 times higher than patients without infection. Burgeoning cost
due to patient's wound care management have fueled the research in finding cost-effective
wound treatments.
The primary objective in the management and treatment of wounds is to attain rapid healing
of the skin with pristine functionality. Acute wounds normally heal in the orderly and
timely natural process of wound healing, however, not all wounds heal satisfactorily. These
chronic wounds present the major economic and ethical problem. Acute wounds heal
through the reparative process of healing involving phases of inflammation, migration,
proliferation and remodeling following the establishment of new skin layers with its barrier
function (Figure 1). On the other side, chronic wounds encounter impaired and delayed
healing due to either local factors such as contamination, or complications namely ulcers
(diabetic, vascular, ischemic or pressure ulcers). This results in need for more long and
careful treatment methods and therapeutic agents for proper recovery of the wound. Recent
advances in the knowledge of pathophysiology of wound have led to the development of
various techniques such as wound dressing. In the recent years, controlled drug delivery
systems have spiked interest in curing the wounds. Several controlled release systems have
been developed for direct sustained delivery of the drugs to the wound site.
Controlled Drug Delivery Systems (DDSs) are developed and designed to deliver drugs at
target site at preset rates for predefined period. They may be classified into two broad
13

categories; targeting and controlled release. Targeted DDSs are the systems which delivers
the drugs to the desired tissues and organs while controlled DDSs are the systems
controlling the release rate of drug (5). The use of these targeted delivery system is highly
beneficial in treatment of chronic wounds as they eliminate the requirement for periodic
administration of drugs in conventional dosage forms. Chronic Wound healing requires
administration of high doses of antibiotics to control infection as chronic wounds lack
sufficient blood supply. Conventionally, drugs are administered systemically into the body
which exposes body to the high dose of antibiotics. Instead of systemic administration,
localized and prolonged delivery of antibiotic is beneficial. In the form of controlled
release system, topical administrations of antimicrobial can be used to avoid side effects of
high dose systemic exposure. Topical delivery of the encapsulated active drug also ensures
the safety of the drug as the skin never gets in contact with the entire drug at a time (6). In
addition, controlled drug delivery systems can be used to provide susceptible drugs such
as growth factors which are unstable but in encapsulated form can be stable. Drug release
profiles can also be altered and tailored according to the needs of the specific situation.
Today, polymeric materials still provide the most important parameters for drug delivery
research, primarily because of their ease of processing and the ability of researchers to
readily control their chemical and physical properties via molecular synthesis (7).

1.1 Wound healing process
The skin is physical barrier present on the human body which provides protection against
the infection and diseases. In the event of an injury, a cascade of events is activated to
repair the wounded tissue. As shown in the figure 1.1, wound healing is a dynamic process
divided into four precise, sequential and regulated stages: (a) hemostasis (b) inflammation
(c) proliferation and (d) remodeling (8, 9). The ideal wound healing events in a healthy
adult are as follows: (a) fast hemostasis; (b) proper inflammation; (c) proliferation and
migration of granulation tissue to the healing site; (d) angiogenesis; (e) rapid reepithelialization and (f) strengthen the healing tissue by synthesis and cross-linking of
collagen in proper order (10).
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When the injury occurs, the process of hemostasis begins immediately with the
vasoconstriction of the broken vessel slowing bleeding. The blood components provide a
temporary plug to the wound site and initiate the wound healing cascade. Platelets at the
injury site aggregate and interact with the soluble blood proteins and surrounding matrix
forming a fibrin clot, and initiating the inflammatory stage (11). The platelets from this clot
and the wound tissues release growth factors such as epidermal growth factor (EGF),
fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and transforming
growth factor-beta (TGF-β) and cytokines. These molecules signals the migration of
inflammatory cells to the wound by chemotaxis endorsing the inflammatory stage (12).
The first inflammatory mediator on injury site are the neutrophils attracted by the signaling
molecules which eliminate the entering microorganisms and cellular debris (12, 13). They
also release reactive oxygen species (ROS) and proinflammatory cytokines for additional
inflammatory cells recruitment (13, 14). The mast cells in this stage are responsible for
release of vascular endothelial growth factor (VEGF), thus increasing in vascular
permeability which is important in cell recruitment from the bloodstream to the wound site
(15). They also signal the recruitment of monocyte from the bloodstream by releasing
signaling molecules such as TGF-β, PDGF, FGF, keratinocyte growth factor (KGF), EGF
and interleukin 1 (IL-1). Monocytes differentiate into macrophages after migrating from
the bloodstream into the wound site where they clear bacteria, debris and apoptotic cells
(including neutrophils) helping to resolve inflammation (16). Apart from their phagocytic
role, macrophages also produce cytokines and growth factors such as TGF-α, TGF-β,
VEGF, FGF and PDGF. The duration of the inflammatory stage vary depending on the size
and severity of the wound but in general takes 24 h to six days after injury to subside (17,
18). The signaling molecules released from the platelets, neutrophils and mast cells in
response to injury causes the recruitment of fibroblasts and epidermal cells, thus
transitioning into the next stage of wound healing – the proliferative stage. The
proliferative stage following the inflammatory stage commences as matrix and tissue cells
migrate into the wound site from the periphery. This phase is characterized by reepithelialization which is the proliferation and migration of epithelial cells over the fibrin
clot. This phase is characterized by the replacement of fibrin clot with granulation tissue
15

(fibroblasts, collagen, and newly formed extracellular matrix (ECM)) (19). In the
regenerating injured tissue, endothelial cells and fibroblasts from the intact margins of
wound site replicate and migrate into wound and secrete proteoglycans and
glycosaminoglycans, the main constituents of ECM such as collagen. Epidermal cells,
mainly keratinocytes are stimulated by the KGF released by fibroblasts as well as IL-1 and
TNF-α released by macrophages and platelets. They proliferate along the wound edges and
create an epithelial bridge as well as accumulate granulation tissue to close the wound
below the fibrin clot (9). The cell and tissue proliferation is supported by the growth of
blood vessels at the wound site. Keratinocytes release VEGF which stimulate the
angiogenesis resulting in migrating of new vessels from surrounding intact capillaries into
the wound site. The wound fibroblasts transition into contractile myofibroblasts which
work to contract the wound edges together (17). The initial dermal tissue reconstruction
begins after 3 to 5 days after initial injury while the proliferation phase can last a few days
to several weeks (17). After ECM proliferation, the wound healing is followed by the last
stage of wound healing which is remodeling phase. In this stage, the collagen
reorganization and maturation occur. The unnecessary collagen and recently formed
capillaries are degraded. The granulation tissue transitions into scar tissue, thus healing the
wound. The remodeling stage can last from a few weeks to several months or a year (17).
The newly closed wound is weaker than the pristine tissue as the tensile strength of scar
tissue is less than pre-injured tissue (8). When the wound healing does not proceed by these
steps, it results in chronic wounds. Depending on the type and size of the wound, the
healing time can differ but no satisfactory reduction in area (20-40%) after 4 treatment
weeks or unhealed wounds up to 4 months are considered to be chronic (10, 20).
In all the chronic wounds, a problem in any stage of the normal wound healing mechanism
causes impaired healing. Wounds are typically struck in two stages which are inflammatory
stage and proliferation stage. Hyperactive inflammatory processes or bacterial infection in
the inflammatory stage while insufficient tissue growth and its integration in proliferation
stage can become the reason the wound is unable to reach the remodeling phase making it
chronic.
16

Figure 1.1. Wound healing process (Hamdan. S. et al. 2017) (21)
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Figure 1.2. Generation of NO during different phases of wound healing (Witte et al. 2002)
(22)
1.1.1

Wound healing complications

One of the characteristic of chronic wounds is chronic inflammation due to an excessive
neutrophil infiltration (8). Although neutrophils are crucial in normal wound healing, their
large volume and prolonged presence has adverse effects. The ECM components and
wound repair mediators (such as VEGF and PDGF) are destroyed by the enzyme
collagenase and elastase released in excessive amounts by neutrophils (23). In addition to
this, surrounding tissues are damaged by accumulation of excessive reactive oxygen
species in the wound (24). Chronic wounds also show abnormal cell growth as the
fibroblasts exhibit low proliferation while keratinocytes at the wound edges showing
hyperproliferation. This results in migration blockade of fibroblasts and keratinocytes into
the wound (23, 24). Low wound fibroblast activity results in decreased angiogenesis and
collagen formation. This leads to inadequate granulation tissue formation and decreased
blood flow to the wound tissues resulting in insufficient wound closure. All this increases
the possibility of tissue breakage as tensile strength of the new tissue is low, resulting in
chronic wound and repeating wound opening process (25).
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The inflow of inflammatory cells to the wound site is rapid as they help in clearing tissue
debris and bacteria to provide clean environment for wound healing. Although bacterial
presence in wound is common, their concentration burden and growth state are critical
factors in making a wound chronic. In acute wounds, bacterial infection is prevented by
the immune system of the body as the bacteria is in free floating or planktonic state (26).
In chronic wounds, the bacterial burden increases so much that the immune system cannot
clear the viable bacteria. For example, in a diabetic patient inflammatory phase in wound
healing is inhibited, impeding the neutrophils and macrophages migration to the wound.
This leads to the decrease in cytokine release as well as low adherence and phagocytosis
causing inefficient bacterial targeting (27). If bacteria remain un-checked in the body, it
has the tendency to attach to wound surface, accumulate and excrete polymeric matrix
forming a biofilm (28). At the outset, the platonic bacteria attach to the surface reversibly
and is susceptible to antibiotics. After initial attachment, within hours it becomes
irreversibly adhered to the surface, multiplying and secreting polymeric matrix,
exopolysaccharide (EPS). Bacteria form microcolonies in the next stage and continue to
secrete EPS causing the formation of thick film (29). A mature biofilm develops as the
bacteria form column like structure due to the film growth. Bacteria begin to detach from
the mature biofilm and spread elsewhere. Penetrating the EPS is harder than destroying
individual bacteria cells which makes bacterial biofilm targeting a challenge for the
immune system (30). The inflammatory response is elevated when the body recognizes the
persistent presence of bacterial biofilm but is ineffective against the biofilm resulting to
chronic inflammation along with the infection (28, 30, 31). A broad variety of bacterial
strains such as gram-positive Staphylococcus aureus (S. aureus) and Enterococcus faecalis
(E. faecalis) as well as gram negative Pseudomonas aeruginosa and Escherichia coli (E.
coli) are found to colonize chronic wounds and lead to biofilm development. Recently, a
common bacterium gram negative Acinetobacter baumannii (A. baumannii) has emerged
infecting wounded soldiers in Iraq and Afghanistan and is now widespread throughout the
U.S hospitals (32-34). Antibiotics have been used widely for treatment of both acute and
chronic bacterial infections, even though not effective equally against both of them (31).
Antibiotics are effective against free floating easily accessible planktonic bacteria, but lost
19

effectiveness against thick matrix of biofilms. They can target dividing planktonic bacteria
but are unable to penetrate the biofilm, thus rendered ineffective against dormant bacteria
in the biofilms (26). Despite their inefficacy, antibiotics are still largely used to treat
bacterial infections where biofilms are present but another more effective method is
required to treat chronic wounds.

1.2 Nitric oxide
The free radical gas nitric oxide (NO) is a small endogenous molecule involved in various
biological functions. It acts as a chemical messenger as it can readily diffuse through cell
membranes especially in the cells of vascular endothelium, immune and neural systems
(35). It acts as a key mediator in cellular communication affecting the functions of these
systems. It also plays important role in regulating processes such as cellular apoptosis and
differentiation (36). NO was once known only as a dangerous pollutant generated by
industries and automotive acting as a potential carcinogen (37, 38). However, the discovery
of its synthesis in mammalian cells and its vital role in the physiological processes attracted
a lot of medical and scientific interest (39). This led to a rapid increase in NO research (40).
Now being one of the important mediators of intracellular as well as extracellular process,
NO has become a major target of the pharmaceutical industry (41).
Endogenous NO is quite unstable having half-life of 1-5 s in physiological environments
and rapidly reacts with biomolecules. Endogenous NO is produced by nitric oxide synthase
(NOS) enzymatically by oxidizing L-arginine to L-citrulline. The three isoforms of NOS:
endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), and
inducible nitric oxide synthase (iNOS) are present depending on the site. The NO generated
by these three isoforms differs in their expression pattern and regulation (42). While eNOS
and nNOS are calcium dependent and constitutively expressed producing low
concentrations for short period, on the other hand iNOS is calcium independent which
produces high amount of NO for longer period (43). As a response to inflammatory
cytokines, iNOS stimulates NO release in epithelial, endothelial and inflammatory cells.
NO can help in the diagnosis of various human diseases such as cardiovascular,
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neurological, gastrointestinal, renal, genitourinary and even cancer (38). There are various
specific functions of nitric oxide, out of which some major is: vascular tone maintenance
by vasodilation, monocyte and neutrophil adhesion inhibitor to vascular endothelium,
inflammation regulator, antioxidative property, neurotransmission regulator, platelet
function regulator (40). Meanwhile, addition to these benefits NO is potentially a toxic
agent. During oxidative stress, O2 intermediates during NO generation which can lead to
antioxidant deficiency (41).
High NO production by iNOS induced by inflammatory cytokines lead to formation of
reactive oxygen and nitrogen species resulting in cellular apoptosis (44). The physiological
activity of NO is concentration dependent. Higher concentration of NO can lead to
cytotoxicity overcoming the protective mechanisms of the cell (45).
1.2.1

Role of nitric oxide in wound healing

Figure 1.2 demonstrates the generation of nitric oxide during the different phases of wound
healing process. The production of NO peaks during the inflammatory stage and diminishes
toward the proliferative stage (22). After the skin injury, iNOS is elevated throughout the
inflammation, granulation tissue formation and re-epithelialization which makes iNOS the
most relevant NOS isoform to the wound healing process. During the inflammatory stage,
iNOS in neutrophils and macrophages is stimulated to produce nitric oxide by cytokines
(such as TNF-α and IL-1) (46-49). NO stimulates the vasodilation of the microvasculature
to increase the blood flow in the wound and aid inflow of inflammatory cells from the
bloodstream (22). The inflammatory stage is dominated by neutrophils and macrophages
while in the proliferative stage fibroblasts are the most active cells responsible for collagen
deposition at the wound site. Wound site fibroblasts have NO releasing capabilities while
fibroblasts in un-injured skin tissue do not. NO inhibition in vivo has shown to impair
wound healing due to decrease in wound collagen production (50, 51). NO is also produced
by the intact keratincytes near the wound stimulating more keratinocyte proliferation and
migration in the wound (48).
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During bacterial infection, iNOS production is upregulated from the macrophages due to
signals from cytokines and bacterial lipopolysaccharides (LPS) which in turn stimulates
the NO production from L-arginine. NO doesn’t have significant direct bactericidal activity
but acts as an intermediate and is part of non-specific immune response. NO helps in
bactericidal action by reacting with the oxygen and oxygen radicals which form reactive
byproducts. NO levels in the healthy tissues are low but during inflammatory conditions,
free radical, reactive oxygen species such as superoxide (O2 -) are produced by
macrophages and neutrophils through NADPH oxidase enzymatic action (44). NO and
superoxide interact to form peroxinitrite (ONOO-) which is strongly antimicrobial. It
induces oxidative stress on DNA nucleotides in bacteria leading to nucleotide cleavage and
cell apoptosis (52, 53). Overexpression of iNOS causes high NO production which reacts
with oxygen species such as superoxide and other biomolecules resulting in the formation
of powerful oxidizing reactive oxygen and nitrogen species. These cause protein oxidation,
DNA base deamination, impaired cellular function, lipid peroxidation, increased
inflammation, enzymes nitrosylation and cell apoptosis (54).
Eukaryotic cells are also susceptible to damage by NO but requires a higher concentration
than the level that damages bacterial cells because of protective mechanisms that scavenge
nitrogen oxygen species (44). In the presence of bacteria products and oxidative stress,
upregulation of thiol protein - metallothionein in eukaryotic cells acts as a protective
mechanism. The thiol on the protein react with the reactive NO byproducts thus reducing
intracellular levels of harmful reactive species (55, 56). This clearly shows that NO plays
a significant role in wound healing which is why utilizing NO in the treatment of chronic
wounds can prove extremely beneficial.
In the past few decades, a lot of research has been done to harness and release NO for the
treatment of wounds. The extended use of NO is unlikely to show any bacterial
resistance as compared to traditional antibiotics and alternatives such as silver (57). The
therapeutic effects of different techniques such as gaseous release, small molecule and
macromolecular NO delivery have been studied. The delivery method, concentration and
time frame are among the several factors which determine the efficiency of the providing
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NO as a therapeutic agent in the wound healing. The simplest path to test NO’s effect on
wound is by administering the molecule in its gas phase (gaseous NO). Although gaseous
NO is relatively easy to administer, difficulty in patient mobility due to equipment size
(NO cylinder) and toxic effect of large quantity of NO limits its usage and require for
sophisticated method.
1.2.2

NO donors and their application

To overcome the limitation in delivery of gaseous NO, material systems incorporated with
NO donors have been studied and developed. The main goal is to develop a material
capable of delivering controlled, predictable levels of NO under physiological conditions
over a given period. The difficulty in non-systemic route of administration of NO is also a
major challenge for administration of exogenous NO. For this reason, NO donors have
been used widely which mimic the endogenous NO production by NOS. NO donors are
functional moieties or small drugs that can generate NO exogenously when administered
(58). There are many classical low molecular weight NO donors which are used, out of
which four major widely used NO donors are diazeniumdiolates (NONOates), Snitrosothiols (RSNOs), metal–nitrosyl complexes, and NO drug hybrids (58). Jones et al.
utilized probiotic NO-releasing patches in which immobilized Lactobacilli ferment glucose
into lactic acid (anaerobic reaction) which in turn reacts to sodium nitrite to produce NO(g)
topically diffusing freely through the adhesive. It may be a safe and cost-effective method
as it showed accelerated wound healing in ischemic wounds of New Zealand's white rabbit
(59).
The process of blending small molecule NO donor into a polymer or synthesizing the
polymer along with the covalently attached NO donor are the primary method of producing
NO from biomaterials. Among various potential NO donors, some compounds have proven
useful for this purpose. Organic nitrates (e.g. nitroglycerin) and nitrites require the
metabolic activation by the enzymes such as mitochondrial aldehyde dehydrogenase
(mtALDH), even with this required conversion, they are widely used NO prodrugs (60).
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Their incorporation in polymer matrices restrict their bioactivation which makes them
somewhat difficult to use.
Topical administration of acidified nitrate cream which generate NO via ascorbic acid
reduction of nitrite to NO found to accelerate wound healing in normal and diabetic mice
(61). It can be useful for targeted NO delivery due to its ease of administration, however,
its use is limited because of cutaneous inflammation and erythema caused at the application
site.
One of the interesting classes of NO releasing molecules for wound healing is
diazeniumdiolates (NONOates) because of their ease of synthesis and predictable,
controlled NO release in aqueous environments. Synthetic NO donors are formed via the
reaction between NO and a variety of different amine groups. Shabani et al. applied a
polyethylenimine cellulose NONOate polymer (PEIC-NO) topically to dermal wounds of
rats showing an accelerated wound closure (62). Additionally, a significant increased
collagen production is observed when human dermal fibroblasts were cultured with a
polyvinyl NONO-ate hydrogel wound dressing. In diabetic mice model these hydrogel
platforms exhibited thicker granulation and scar tissue but no significant increase in wound
closure time (63). In another study, poly (lactic-co-glycolic acid)-polyethylenimine (PEI)
nanoparticles (NO/PPNPs) incorporated with NONOate were developed which showed
extended NO release for over 6 days (64). They were found to have a propensity to bind to
negatively charged methicillin-resistant staphylococcus aureus (MRSA) and P. aeruginosa
surface due to positive charge of nanoparticles. This showed bactericidal efficacy of
nanoparticles without any toxic effect to fibroblast cells and favorable wound healing in
MRSA-infected full-thickness wounds.

Regardless of their advantages, potential of

carcinogenic nitrosamine formation due to NONOate decomposition products interaction
hinders the clinically use of many NONOates.
1.2.2.1 S-Nitrosothiols
S-Nitrosothiols (RSNOs) are thiol derived endogenously produced class of NO-releasing
compounds. S-Nitroso-N-acetylpenicillamine (SNAP) is an example of an RSNO shown
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in Fig 1.3. These NO donors (RSNO) are known to release NO through thermal, photolytic,
and transition metal decomposition pathways (65). RSNOs can be characterized by UVVis spectroscopy. The primary RSNO group exhibit a π→π* transition centered near 340
nm (major peak). A less significant second smaller peak due to the n→π* transition occurs
near 550 nm in primary and secondary RSNOs (66). RSNOs display either a red/pink
(primary and secondary) or green (tertiary) color because of the visible range absorbance.
The copper (metal) ion mediated and ascorbic acid mediated decomposition are the two
mechanisms of NO release from RSNO. Cu+ decompose the RSNO into nitric oxide and
the corresponding disulfide (65).
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Figure 1.3. S-Nitroso-N-acetylpenicillamine (SNAP)
S-nitrosothiols react with ascorbic acid in two reactions depending on the latter's
concentration.
At low concentration, ascorbate acts as a reducing agent which generates Cu+ from Cu+2,
thus decomposing RSNOs into nitric oxide and the corresponding disulfide, whereas at
higher ascorbate concentration, the reaction is independent of Cu+2 and products formed
are nitric oxide and the RSNO derived thiol (66). Another pathway for NO release from
RSNOs is via photo initiated decomposition. This is a crucial factor as light can act as an
on/off switch to generate NO in a controllable manner whenever needed. This avoids the
need of other NO release triggering mechanisms (67).
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2 RSNO → 2 NO + RSSR
Frost et al. showed photo initiated NO release from a tri-layer silicon rubber film in which
one layer blended with S-Nitroso-N-acetyl-D,L-penicillamine derivatized fumed silica was
sandwiched between two layers of pure silicon rubber without need of Cu ion and
ascorbate. Intensity and duration of the light exposed to the film determined the amount of
NO generated (68). Gierke et al., covalently linked a S-Nitroso-N-acetyl-D-penicillamine
to polydimethylsiloxane and developed a photo initiated NO releasing polymer material
(SNAP-PDMS) (69). A number of RSNO based NO releasing biomaterials have been
proposed for wound healing application with antithrombotic and antibacterial activity.

1.3 Microparticles drug delivery system
1.3.1

General

Several NO releasing materials such as polymeric nanoparticles, dendrimers, inorganic
nanoparticles (metallic nanoparticles, silica nanoparticles, liposomes, carbon nanotubes
and quantum dots have been described in different research articles (40, 70-75). Their
synthesis, characterization and application for NO delivery have been thoroughly studied.
However, their use in the wound healing is still a relatively novel approach which has yet
to be explored.
Microparticles (also known as microspheres) are the small, spherical particulate system
with the diameter ranging in the size of 1μm -1000μm. They have been proven ideal in
providing sustained and controlled release. In recent years, polymeric microparticles have
gained a great deal of interest in the field of drug delivery because of their well-defined
production parameters to obtain desired size ranges (76). The freedom to control the
dimension of the microparticles makes their injectability easier. They hold a wonderful
opportunity due to their drug reservoir and bioactive molecule carrier ability as well as
their controlled drug release characteristics. The release from the particles can be achieved
either by degradation of the polymer matrix or leaching of the drug from the particles (77).
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Different biodegradable carrier matrices have been used for the microparticle production
(synthetic or natural) in therapeutics delivery (78). Natural polymers such as collagen,
chitosan, alginate and proteins used in microparticle production undergo enzymatic
degradation while hydrolytic degradation happens in synthetic polymers such as polylactic
acid (PLA), polycaprolactone (PCL), polyglycolic acid (PGA) and polylactic-co-glycolic
acid (PLGA).
Microparticles are an attractive drug delivery strategy for a variety of drugs including
proteins, peptides, hydrophilic and hydrophobic small molecules. Alteration in the polymer
weight, hydrophilicity and particle size can directly control the release of the therapeutic
molecule carrying by the microparticle. Microparticle protects the encapsulated drug
against degradation, offers controlled and local delivery over periods and simple
administration compared to alternatives such as macro sized implants. Polymeric systems
can incorporate hydrophilic and lipophilic drugs with relatively high efficiency. A drug can
be homogeneously distributed throughout the polymer matrix (microparticles) or form a
drug reservoir by encapsulating into polymer (microcapsules). These properties make
microparticle drug carriers potentially tunable in controlling dose and rate of drug delivery.
1.3.2

Different preparation methods of polymeric microparticles

Microparticles are usually a homogenous mixture comprised of two main components:
polymer and active agent. The core of the microparticle may be solid, liquid, or even gas
(79). There are various methods employed for preparation of microparticles for different
biomedical applications. The employed method used to encapsulate the drug in the polymer
matrix should meet the following requirements (80, 81):
1) The processing parameters of the microparticle fabrication must not affect the stability
and biological activity of the drug.
2) The encapsulation efficiency of the drug and yield of the microparticle should be high
enough and in the desired range respectively.
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3) The microparticle characteristics (such as quality and the drug release profile) should be
highly reproducible.
Some of the basic polymeric microparticle fabrication methods are described below:
1.3.2.1 Coacervation (precipitation by non-solvent addition)
In this method solid crystals or aqueous solution of the drug is dispersed in an organic
polymer solution following an addition of second organic solvent (non-solvent) in which
polymer is insoluble thus causing phase separation. A phase inducer (e.g. mineral oil) is
added to induce coacervation. Due to insolubility of hydrophilic drugs, high encapsulation
efficiency can be obtained by this method, however high cost of handling oils, high
microparticle aggregate formation and difficult to control parameters makes it less
promising. The parameters which affect the outcome of this method are the drug: polymer
ratio, the polymer solvent, the process temperature, stirring rate or the non-solvent volume
or type.
1.3.2.2 Emulsion salting out
In this technique, polymer is dispersed in water miscible organic solvent along with the
drug. This drug containing polymeric organic solution is emulsified into an electrolyte
(magnesium acetate, calcium chloride, sodium chloride, magnesium chloride) saturated
aqueous solution (82). A stable oil in water (O/W) emulsion is produced due to the salting
out effect which prevents mixing of polymeric organic solvent with an aqueous phase
saturated with electrolytes. An excessive amount of water is added to the emulsion which
induces reverse salting out effect leading to the formation of microparticles as the water
miscible solvent diffuses into aqueous phase from the emulsion droplets. The dissolution
of polymer in nonhalogenated solvents and no requirement for high energy/pressure device
for emulsification are advantages of this method, however, there is concern about the
recycling of massive quantities of salt used can be a problem.
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1.3.2.3

Spray drying

In spray drying, organic polymer solution along with suspended drug is spray dried to form
the microparticles. Compared to O/W emulsion evaporation technique (unsuitable for
hydrophilic drugs), spray drying can incorporate both hydrophilic and hydrophobic drugs
in the microparticles. The organic solvent used in spray drying should evaporate quickly
in the drying phase so solvents such as methylene chloride or ethyl acetate should be used
to dissolve polymer. For example, NO donor containing inhalable PLGA microparticles
produced by spray drying have been shown to target and control release of NO to the
macrophage for killing intracellular Mycobacterium tuberculosis (83). But there are few
draw backs of this method such as formation of needle shaped crystals due to
incompatibility of drug and polymer, and fibers formation due to insufficient dispersion
force which break up polymer solution (84).
1.3.2.4

Solvent partitioning precipitation

In solvent partitioning, a drug containing polymer in organic solvent solution is slowly
injected into a stream of mineral oil or vegetable oil.

The drug and the polymer

coprecipitate as the organic solvent is soluble in oil while drug and polymer are not which
led to their partitioning in oil. The solubility of the drug is a crucial factor in this method.
The drug will precipitate along with polymer if it is soluble in polymer solution while the
polymer will precipitate around solid drug if it suspended in solution. The size of the
microparticles in this method are affected by the drug: polymer ratio, diameter of the
needle, choice of organic solvent and flow rate of the mineral oil (85).
1.3.2.5 Supercritical fluid extraction method
Supercritical fluids are the substances which are above their critical point (T>Tc). These
show gaseous flow properties and liquid’s dissolving power. These have no surface tension
which make them easily penetrable through the materials. At critical point they experience
changes in their density which relates to their solvent power which can be controlled by
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temperature and pressure. (86). There are two major two techniques used in SCF. The first
is to dissolve the drug and polymer in the SCF and then fast expansion of supercritical
solution (RESS) following spraying the melt forming particles. The second is to melt the
drug and polymer in SCF and then precipitating the particles from gas saturated solution
(PGSS) after releasing the gas (87). This method requires special equipment and therefore
are not widely used on the bench scale.
1.3.2.6

Solvent evaporation method

The solvent evaporation method has been widely explored for the polymeric microparticle
preparation in delivering different drugs (80, 87, 88). There are several variable parameters
which affect the properties of the microparticles that are drug solubility, solvent type,
polymer composition (type, viscosity and molecular weight), diffusion rate, temperature,
stirring rate, internal morphology and drug loading (81, 84, 87, 89). The successful
entrapment of the drug into the microparticles defines the productiveness of this method to
produce microspheres. The drugs which are either insoluble or poorly soluble in the
continuous phase (i.e. the aqueous medium) have been most successfully encapsulated
using this process (90). Several types of drugs and active agents have been formulated into
polymeric systems, including nitric oxide releasing agents (74, 91, 92). Different solvent
evaporation techniques are available for microparticle preparation depending on the
hydrophobicity or the hydrophilicity of the drug for efficient drug encapsulation.
1.3.2.6.1 Single emulsion
Single emulsion process involves oil-in-water (O/W) emulsification. In this system,
polymer and drug (to be encapsulated) are dissolved in a volatile solvent (i.e., organic
phase) and emulsified in a surfactant containing aqueous phase. This method is suitable
and frequently used for encapsulating insoluble or poorly water-soluble and lipid soluble
drugs.
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This is the simplest method among all emulsion techniques and other methods are variation
of the single emulsion. This system involves four major steps: (a) polymer and
hydrophobic drug are dissolved in an organic solvent; (b) organic phase, called dispersed
phase, is emulsified in an aqueous phase called continuous phase resulting formation of
droplets; (c) solvent is extracted from dispersed phase by solvent evaporation, thus
hardening droplets into particles and (d) microparticles are recovered and dried by
eliminating the residual solvent.
In most systems to prepare microparticles using oil in water emulsions, the components
necessary are organic phase (polymer and drug dissolved in a volatile solvent), a surfactant
dissolved in an aqueous phase. This organic and aqueous phase are mixed to form emulsion
(O/W) by appropriate stirring using a propeller or a magnetic bar at suitable temperature
conditions. A surfactant is amphipathic in nature and is added into the aqueous phase to
stabilize the formed droplets and prevent them from coalescing and microparticle
flocculation. Surfactants align at the droplet surface and lowers the free energy at the
interface between the two phases, thus promote their stability. One of the widely used
surfactant is poly vinyl alcohol (PVA).
After the emulsion formation, solvent removal is done by either evaporation or extraction
to harden the droplets. The solvent removal by evaporation involves maintaining the
emulsion at a reduced or atmospheric pressure to evaporate the volatile solvent. This results
in the evaporation of the organic solvent at the water-air interface after its leaching out of
the droplet into aqueous phase. On the other hand, in extraction, the emulsion is added to
a large quantity of water which causes the organic solvent to diffuse out of the oil droplets.
The extraction method depends on the following factors: the temperature of medium/water,
emulsion volume to extraction medium ratio and the solubility of the polymer, solvent and
the dispersed phase. Extraction method is faster than evaporation process, however the
microparticles made by extraction are more porous which can lead to undesirable drug
release profiles. The formation of particles with a high porosity will occur due to high
extraction leading to undesirable drug release profiles (93).
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The major disadvantage of O/W emulsification process is the poor encapsulation of the
hydrophilic drugs. One reasons can be the hydrophilic drug not dissolving in the organic
solvent. Other being, hydrophilic drug diffusing or partitioning out from the dispersed
organic phase into the continuous aqueous phase resulting in loss of the drug and
deposition of microcrystalline fragments of the drug onto the microsphere surface which
causes initial burst release of the drug (81). Four alternative methods have been described
and employed to increase encapsulation of hydrophilic drugs. These methods are water-inoil-water (W/O/W) emulsion, o/w co-solvent method, oil in oil (O/O) emulsion, and waterin-oil (W/O) emulsion (94).
In the co-solvent system, the drug (which is not soluble in one organic solvent) is dissolved
in a second solvent (co-solvent). In oil in oil (O/O) emulsion method, the drug can be
dissolved or suspended in oil phase and then emulsified in another oil phase (87). Another
method known as water-in-oil (W/O) emulsion is also employed in which polymer and
drug are solubilized in water-miscible organic solvent (such as acetonitrile) and then
dispersed in oil following the evaporation of organic solvent from dispersed phase and
washing off the oil by solvents (such as n-hexane) (80).
1.3.2.6.2 Double emulsion
For hydrophilic or drugs insoluble in organic solvent, a double emulsion process is used.
One method which can be employed is solid-in-oil-in-water emulsion (S/O/W) process
provided the size of the drug form is small (1-10 μm). A very low drug particle size is
necessary for high encapsulation in desired microparticles. Both hydrophilic drugs
(cisplatin) and hydrophobic drugs (87) have been encapsulated using this method. The
number of drug properties including parameters affecting this method are properties of the
drug crystal such as their hardness, elasticity, melting point, hygroscopicity, and
decomposition due to thermal or light sensitivity. A smooth mortar and pestle can be used
for a non-hygroscopic drug while a ball mill apparatus can be used for hygroscopic drugs.
However, there are certain drawbacks of this method such as ball mill is low efficient in
terms of drug recovery, drug might get contaminated while size reduction process (ex. wear
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and tear of the ball), drug might show sedimentation (higher density) or flotation (low
wettability) (87).
Another method to encapsulate hydrophilic drugs is water-in-oil in water (W/O/W)
emulsion process. In this process, firstly a W1/O primary emulsion is formed by mixing an
aqueous drug solution (W1) to an organic solvent containing polymer (organic phase)
along with the stirring or sonication. This primary emulsion is then dispersed in another
surfactant containing aqueous phase (W2) to form the W1/O/W2 emulsion. This method is
widely used to encapsulate peptides and proteins at high encapsulation efficiency (87). The
main drawback of this method is stabilization of the inner emulsion which can result in the
loss of drug containing aqueous droplets to the external aqueous phase (W2). A surfactant
that dissolve in the organic solvent (such as sorbitan) can be used to stabilize inner
emulsion.

1.4 Microparticles preparation by solvent evaporation method
1.4.1

Materials

1.4.1.1 Dispersed phase
1.4.1.1.1 Polymer
One of the major deciding factor in encapsulating a therapeutic agent in microparticle is
the polymer used. Different polymer parameters such as type of polymer, molecular
weight, composition (homopolymer or copolymer), concentration and hydrophilicity
influence the encapsulation of drug in microparticle. The type of polymer and its
degradation properties affect the drug release rates. Degradable polymers can be
categorized in two groups depending on the rate of their functional group hydrolysis:
surface (heterogeneous) eroding and bulk eroding (homogenous) (95). Surface eroding
polymers (ex. polyanhydrides and poly (ortho esters)) degrade from the surface only as
they are composed of hydrophobic monomers while bulk eroding polymers (ex. PLA,
PLGA) degrade throughout the polymer matrix. Surface eroding polymers degrade into
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oligomers and monomers at polymer-water interface as water is not able to penetrate the
polymer matrix whereas in bulk eroding polymers water permeates through polymer and
degrades throughout the matrix. Surface eroding polymers are fast degrading compared to
bulk eroding polymer due to their composition (more hydrophobic monomers) (95).
Polymer molecular weight, concentration and hydrophilicity affect the degradation rate,
encapsulation efficiency and drug release rates. Usually, high polymer weight and
concentration show increased encapsulation efficiency and low initial burst release.
Increase in hydrophilicity increases the degradation rate of polymer and high release rate
(76).
1.4.1.1.2 Solvent
An acceptable solvent required for the solvent evaporation technique should meet
following criteria: ability to dissolve the polymer, poor solubility in continuous phase,
highly volatile and low boiling point, low toxicity (94). Chloroform has been used
frequently as a solvent but has been replaced with dichloromethane due to former’s toxicity
and low vapor pressure. Dichloromethane shows high volatility, poor miscibility with
water and low boiling point which has made it the most common solvent for solvent
evaporation technique. However, due to carcinogenic nature of dichloromethane, less toxic
solvents such as ethyl acetate have also been studied as a potential substitute. Although
less toxic, ethyl acetate shows partial miscibility in water (4.5 times higher compared to
dichloromethane) which decreases the encapsulation efficiency of microparticles and are
non-uniform. So, currently dichloromethane is the most used solvent because of fast
evaporation, high drug encapsulation efficiency and more spherical and uniform form
microparticles (94).
1.4.1.2 Continuous phase
1.4.1.2.1 Surfactant
Surfactants are used in the solvent evaporation method to stabilization of the dispersed
phase in the continuous phase. It stabilizes the emulsion by reducing the surface tension of
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the continuous phase, thus avoiding the coalescence and agglomeration of the dispersed
droplets. They are the amphiphilic in nature and are chosen based on polarity of both
immiscible phases, microparticle desired size distribution and sphericity (94). In literature
surfactants are divided into four types depending on the nature of their hydrophilic
molecule part: anionic, cationic, amphoteric and non-ionic. For ex. PVA (polyvinyl
alcohol) is the most used surfactant. The microparticle size decreases with the increase in
surfactant concentration as it lowers surface tension of continuous phase until critical
micelle concentration (CMC) is reached. Surface tension does not decreases after reaching
critical micelle concentration (CMC) (94).
1.4.2

Operating conditions

1.4.2.1 Agitation
Agitation is an important parameter for controlling the microparticle size. Li et al. (2008)
also reported agitation to be one of the most important parameter for controlling the
microparticle size only next to the physicochemical properties of materials. Factors such
as container geometry; position, number and size of impeller; impeller to container
diameter ratio determines the size distribution of the droplets formed in the emulsion. The
increase in agitation rate decrease the average microparticle size (94).
1.4.2.2 Temperature and pressure
The evaporation rate of the solvent during the microparticle formation can be accelerated
either by increasing the temperature of the continuous phase or by reducing the reactor
pressure. However, elevated temperature can result in lower yield, larger size distribution,
lower drug encapsulation efficiency and coarser morphology (96). It can result in
denaturation or degradation of the drug. Applying reduced pressure can be an option as it
increases encapsulation efficiency. But, it is not easy and lowering pressure compared to
the saturated vapor pressure of the solvent at a given temperature can boil the solvent (94).
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1.5 Poly (l-lactic acid)
Biodegradable polymers have gained wide use in biomedical and pharmaceutical industry.
A suitable biodegradable polymer would have following properties:
(1) Metabolization and elimination from the body by normal physiological pathways
(2) Easy fabrication
(3) Degradation into non-toxic substances
(4) No inflammatory reaction after application
(5) Degradation product of the biodegradable polymer should be carbon dioxide and water.
According to these criteria, polylactide (PLA) and their co-polymers are considered as
suitable biodegradable polymers. PLA has asymmetric α-carbon which can be described
as d- or l- stereochemical centers (or R or S, respectively) resulting in two enantiomeric
forms of poly D-lactic acid (PDLA) and poly L-lactic acid (PLLA). PLLA is crystalline or
semi crystalline while PDLA is completely amorphous due to disordered polymer chains.
Fig 1.4 shows the structure of PLLA. PLLA has melting temperature (56) of approximately
150°C and a glass transition temperature (Tg) of approximately 50°C. Due to crystallinity,
PLLA is less permeable compared to the amorphous polymers. Crystallinity of PLLA also
gives its mechanical strength and stiffness properties. Poly (l-lactic acid) (PLLA) has been
widely

studied

for

drug

delivery

because

of

its

biodegradability

and

biocompatibility. Molecular weight of the polymer is directly related to polymer chain size
which affects the degradation rate. High molecular weight polymers require more time to
degrade. However, for PLLA this effect is opposite because of inverse relation of
crystallinity with molecular weight. PLLA which is pure polymer is likely to sustain the
drug release for longer period due to its longer degradation half-life (97).
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Figure 1.4 Structure of PLLA

1.5.1

Drug release from PLA devices

Polymer degradation is the breakdown of polymer chains into oligomers and monomers
resulting in decrease in molecular weight after degradation. After degradation, erosion
occurs in the polymer which is the loss of material from the polymer bulk resulting in
weight loss.
The drug release from the PLA devices occur using two main mechanisms: diffusion and
degradation/erosion. At first the drug release is diffusion controlled and at the end it is
degradation/erosion controlled. Drug release from the PLA device starts with the water
absorption following hydrolysis and erosion. The drug release profile of PLA device
degradation is mostly tri-phasic, sometimes bi-phasic which are first order release kinetics
and rarely mono-phasic which is zero-order release kinetics. Tri-phasic profile is observed
usually in large particles as heterogeneous degradation occurs inside the particles while biphasic release profile is observed in smaller particles. Thus, alteration of release profile can
be done by using different sizes of particles (98).
There are three distinct phases of drug release: burst release, slow release and second burst.
In the first phase i.e. burst release free, non-encapsulated drug from and/or near the surface
of the particles is released. It can also happen due to the crack formation or disintegration
of the device. The burst release results in faster drug release in the medium immediately
after exposure which decreases the lifetime of the device. It is usually an undesirable
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negative phenomenon. However, initial burst is sometimes desirable such as in cutaneous
wound healing which can provide immediate relief followed by prolonged release to
promote gradual healing (99, 100). The main disadvantages of the burst release are
unpredictability and uncontrollable amount of drug release. It may be controlled or avoided
by different methods (76, 87).
In the second phase, also called lag-phase drug diffusion occurs slowly through the
polymer or the pores due to polymer hydration. It is slow release phase and degradation of
the polymer occurs simultaneously (98). Third phase also known as second burst is fast
release phase which marks the beginning of polymer erosion. In this phase, drug is now
released by both diffusion and erosion as polymer is hydrolyzed to oligomers and
monomers. Evidently, not all the drug release profiles follow the traditional tri-phasic
release profile. In cases of rapid, short or absence of second release phase, release may
slow down at the end. Several factors affect the drug release profile which make release
profile prediction very difficult.

1.6 Hydrogel
Hydrogels are hydrophilic three-dimensional, and crosslinked polymer networks that can
absorb significant amount of water or biological fluid up to 90 % of their dry weight. They
are soft and elastic material usually used above their glass transition temperature. They
have the capability to absorb water attributed to the presence of hydrophilic side groups
(hydroxyl, carboxyl, amide and sulfonic groups) connected to the polymer backbone (101).
Crosslinks present in the hydrophilic hydrogel make them insoluble in aqueous
environment to maintain their structure. Because of their structural (compositionally and
mechanically) similarity to the living tissue (extracellular matrix) and ability to promote
cell adhesion and proliferation, the hydrogels have gained wide interest in the field of tissue
engineering and drug delivery (101).
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1.6.1

Classification of hydrogels

Hydrogels can be classified based on a variety of their characteristics such as nature of
material, nature of side groups, mechanical and structural features, method of preparation,
physical structure, crosslinking and their responsiveness to the physiological environment
stimuli (101).
The simplest way to classify the hydrogel is based on origin of polymer: natural or synthetic
(101). Natural polymers are obtained from recyclable material such plants and animals.
The hydrogel of natural polymer is biocompatible, biodegradable and have bioactive site
in their structure but mechanically weak compared to synthetic polymers. Whereas the
synthetic hydrogels have well known structures which enable their modification for
required properties. Some examples of natural polymers include agarose, alginate,
chitosan, fibrin, collagen and hyaluronic acid while Synthetic polymers include poly
(ethylene glycol), poly (ethylene oxide), polyvinyl alcohol, polyacrylates and polypeptides
(101).
Based on the nature of side group, the hydrogel can be classified as neutral, cationic,
anionic or ampholytic. On the basis of preparation method, hydrogel may compose of one
type of monomer (homopolymer), two types of monomers (copolymer), and more than
three types of polymer (multipolymer). One type of polymer can be synthesized or
crosslinked in the presence of another inflated polymer network (101). At Least one type
of polymer must be hydrophilic in each type.
Based on the configuration, hydrogels are classified on the basis of physical and chemical
structure which are amorphous, semi crystalline and crystalline (101).
Classified on the basis of cross linking hydrogels are divided in two categories: chemically
cross-linked hydrogels and physically cross-linked hydrogels chemical crosslinking means
covalent bond formation between different functional groups of polymers (101). It can be
done by different methods such as free radical polymerization, high energy irradiation,
enzymes use and complementary groups’ chemical reaction. Physically cross-linked
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hydrogels are usually the biodegradable hydrogels which do not need any external crosslinking agent. Cross-linking agents can be toxic and non-biodegradable and often requires
their residual removal before their use in the biomedical industry. Highly ordered and
assembled chain segments in polymer are held together by secondary molecular forces such
as hydrogen bonding, Van der Waal forces or hydrophobic interactions which keep
together their amorphous hydrophilic phase (101).
Another way to classify hydrogel is to divide them based on their responsiveness to the
external environment stimuli. Stimuli responsive hydrogels are stimuli sensitive that are
able to sense and express varying degree of response to even minor changes in the external
environment conditions such as physical stimuli (temperature, electric or magnetic field,
light, pressure, and sound) or the chemical stimuli (pH, solvent composition, ionic strength,
and molecular species).
Temperature responsive hydrogels: These exhibit temperature dependent sol-gel transition
Tgel, which correlate to the lower critical solution temperature (LCST), and gel-sol
transition temperature Tp (upper critical solution temperature, UCST), which correlates to
dissipation or precipitation of a gel (102). The H2O molecules bonds with the polar groups
of the polymer through hydrogen bonding at temperature below LCST. With the increase
in temperature above LCST, these polymer network collapse as the hydrogen bonds release
to the bulk leading to large gain in entropy. Some examples of thermoresponsive hydrogels
are hydrogels containing polymers such as chitosan PEG-poly, N-isopropylacrylamide
hydrogel (PNIPAA), methyl cellulose. They can have useful applications in sustained drug
delivery and tissue engineering (103).
pH responsive hydrogels: The functional group of a polymer in pH responsive hydrogel is
added to a weak acidic group (ex. acrylic acid) or weak basic group (ex. amine). It results
in sudden swelling of the polymer due to change in pKA and pH. Some polymers have
carboxylic acid as functional groups which accept hydrogen at low pH. They exchange
carboxylic ion for cation above pKA value and become ionized at higher pH. As the
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carboxyl groups gets ionized, the volume and swelling capacity of these polymers increase
till it reaches a plateau near pH 7 (102).
1.6.2

Hydrogels in wound therapy

The hydrogel structure can have structural similarity to ECM due to their high water
content (104). They have a key role in tissue engineering as they can help in cellular
recognition by acting as an artificial ECM. A hydrogel must meet certain criteria to
promote new tissue formation which include physical, biological and biocompatibility
parameters.
Hydrogel can be real helpful in the treatment of the wound. They are appropriate for
cleaning a dry, sloughy or necrotic wound through dead tissue rehydration. They can
increase autolytic debridement and provide coolness to the wound surface leading to a
noticeable pain reduction and increasing patient acceptability. Hydrogels do not adhere to
the wound if required can be easily removed due to their chemical properties. The
hydrogels which fulfill all these parameters are suitable to be used as ‘ideal dressing’ (105).
Some commercially available hydrogels for skin regeneration are TegadermTM Hydrogel
Wound Filler (3M), DermagelTM Hydrogel Sheets (Medline Industries), and
AquaDermTM Hydrogel Sheet (DermaRite).
Hydrogels can be used as drug delivery systems which can be used for controlled delivery
and release of bioactive molecules into the wound (106). In majority of cases, Slow release
profile of bioactive molecules is desirable to assure their presence during the required
whole period of healing. For this objective, some researchers have incorporated growth
factors (VEGF, FGF etc.) in the hydrogel. These growth factors are released along the
entire wound healing process and are important in the process. Topical delivery of FGF
using glycosaminoglycan hydrogel by Liu et al. demonstrated its potential in compromised
wound healing patients (107). Hydrogels can be incorporated with RGD sequences similar
to natural ECM to enhance cellular recognition of ECM and to promote cell adhesion (108).
Due to their properties, hydrogels are a good potential candidate for protein/drug release
as they are able to maintain protein structure and drug activity. The rate of release from
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the 3D matrix of the hydrogel is generally diffusion controlled through aqueous channels
within hydrogels (109). Therefore, it is difficult to control the release of protein/drug over
a long time using hydrogel. To overcome this limitation, different strategies such as
microparticle incorporation in the hydrogel have been studied (110). As shown in Fig 1.5,
microparticles can be encapsulated with the drug can be embedded in the hydrogel.

Figure 1.5 Microparticle encapsulation in hydrogel

Microparticles, nanoparticles and liposomes have been studied and developed as controlled
drug release systems. Therefore, these carriers can be incorporated in the hydrogel to avoid
a burst release of bioactive molecules from hydrogel. The carrier entrapment in the
hydrogel network enhances the efficiency of bioactive molecules release in vivo at the
targeted site. Moreover, hydrogel support the carrier, increases stability of the bioactive
molecule within carrier and provide an extra diffusion barrier for drug release which
increases the drug release period. Alongside, it allows the scaling down of therapeutic dose
administered to the patient (111). Bae et al. developed a sustained drug delivery system by
incorporating PLGA microparticles a sustained release system for local drug delivery that
incorporated model drug (5-fluorouracil) loaded PLGA microparticles into thermosensitive
chitosan hydrogel. This system demonstrated a decrease in the drug burst release and was
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proposed to be used as an injectable drug carrier system (112). After considering the
excellent properties and sustained bioactive molecule release applications of hydrogel in
wound healing, these systems will be further studied for its future application in biomedical
and clinical industry.
1.6.3

Chitosan

Chitosan is a linear polymer of β-(1-4) linked D-glucosamine residues and N-acetyl-Dglucosamine groups (Fig 1.6). It is a natural, semi crystalline and positively-charged
polysaccharide made by deacetylation of chitin, a component present in the exoskeleton of
crustaceans. The major parameters affecting the chemical characteristics of chitosan are its
molecular weight and degree of acetylation. Depending on degree of deacetylation,
chitosan is commercially available in low molecular weight, medium molecular weight and
high molecular weight (113). When using chitosan as a dressing for wound treatment
degree of deacetylation is a crucial factor.
The size of Chitosan polymer molecules is large. The water holding capacity of high
molecular weight (HMW) chitosan in a hydrogel is more compared to a low molecular
weight (LMW). Chitosan molecules can form bonds or interaction with other molecules as
the chitosan deacetylation results in appearance of amino groups. Amino groups have an
antimicrobial effect. Therefore, degree of deacetylation is a key factor in anticipating the
extent of wound healing acceleration by the hydrogel. Chitosan with high degree of
deacetylation can be a desired parameter for gel preparation for wound treatment (114).
Chitosan is insoluble in inorganics and at neutral pH but is soluble in weak acids such as
acetic acid (115).
Chitosan can aid to wound healing as it stimulates hemostasis and accelerates tissue
regeneration. A natural product is often preferred over a synthetic material for biomedical
research due to its biocompatibility. Chitosan is biodegradable as it can be metabolized by
human enzymes (such as lysozyme) and is non-toxic. The chitosan has been approved by
FDA in the USA for use in wound dressings (74, 75). Chitosan preparations are shown to
be toxic to bacteria, fungi and parasites. Its structural similarity to glycosaminoglycan’s
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and hydrophilic nature makes it an attractive material for a tissue engineering scaffold. Nacetylglucosamine is an anti-inflammatory drug which is monomeric unit of chitosan can
help in wound repair.
Chitosan may provide a cool and soothing effect when applied to an open wound inducing
an analgesic effect. When applied as a topical agent on open wound such as skin burns and
ulcers, excellent pain relief was observed by chitosan (70). Due to anti-inflammatory
effects of chitosan, these are beneficial for the treatment of prolonged inflammation at the
wound site. Water-soluble chitosan has shown to significantly suppress the expression and
secretion of proinflammatory cytokines Water-soluble chitosan significantly suppresses
the secretion and expression of proinflammatory cytokines (tumor necrosis factor-α and
interleukin-6) and inducible nitric oxide synthase in astrocytes (70).
Chitosan has an antimicrobial activity due to presence of its cationic nature. The cationic
amino groups of chitosan bind to the anionic groups of the bacteria causing the inhibition
of growth of these bacteria which can be useful during the infectious period of a burn
wound, as bacterial infection may delay the healing. This positively charged nature of
chitosan due to cations also facilitate the effective cell growth and protein
attachment. Ribeiro et al. developed and studied the chitosan hydrogel wound dressing on
the isolated fibroblast cells from rat skin to assess the cytotoxicity of the hydrogel. The
results displayed cell adhesion and proliferation was promoted by the chitosan hydrogel
and cell viability studies showed non-cytotoxic nature of hydrogel and its degradation byproducts. This suggested that chitosan hydrogel may help in skin regeneration (116). Both
either blending or crosslinking of chitosan with other polymers are effective procedure to
enhance its physical and mechanical properties along with expanding its area of application
(117).
It could also form polyelectrolyte complexes with various natural and synthetic polymers
which can have various applications in biomedical (drug delivery) and medicine industry
(118). Many altered chitosan hydrogels exhibit thermosensitive characteristics. For
example, Bhattaraim et al. developed a copolymer by grafting PEG onto the chitosan which
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resulted in a thermally reversible hydrogel with LCST of 34°C. This injectable thermogel
was studied for in vitro drug release of model protein bovine serum albumin (119).

OH
NH2
O
O
OH

OH
O

O

NH2
OH

n

Figure 1.6 Structure of Chitosan

1.6.4

Agarose

Agarose is a natural polysaccharide consist of repeating units of alternating β (1-4)-linked
D-galactose and α (1-3)-linked 3, 6 anhydro-L-galactose residues. It is a neutral
polysaccharide obtained from marine red algae (e.g. Rhodophyta). Agarose exhibit LCST
at 35°C similarly to other temperature sensitive hydrogels. The agarose hydrogel can be
hydrophilic, hydrated and swollen below LCST while it collapse, gets hydrophobic and
dehydrated (120). The process of gelation is fully reversible without any change in polymer
properties.
Agarose can undergo coil-helix transition which makes agarose hydrogels concentration
and temperature. The agarose structure becomes more ordered due to conversion of coils
to helices through hydrogen bonds. It also affects the mechanical properties of the hydrogel
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(121). Agarose undergo thermoreversible gelation in water environment. Agarose chains
are in random coil state at elevated temperature and assemble themselves in left handed
dual helices as temperature decreases due to hydrogen bonding and Van der Waal
interactions. This helices network becomes more stable and rigid because of further
aggregation due to long range interactions leading to hydrogel formation. Again, heating
destroys the helices in the hydrogel causing the random coil chain formation.
The agarose polymer concentration, pH and solvent type also affects the thermal and
mechanical properties of the agarose hydrogel. The biocompatibility and capacity of
agarose to form very strong gels, even at low concentrations, make it suitable for Tissue
Engineering applications. Agarose has shown to support non-immunogenic neurite
extension and widely studied in nerve tissue regeneration applications. However, agarose
hydrogel show very low cell adhesion and slow degradation rate (122). According to
numerous studies agarose itself does not contain cell adhesive amino acid which results in
agarose hydrogels not supporting enough cell adhesiveness and proliferation (123). To
overcome this limitation, agarose can be modified by either chemically functionalizing
with the peptides containing cell recognition motif such as RGD or combining with other
polysaccharides. A chitosan-agarose composite hydrogel system developed by GómezMascaraque et al. displayed cell adhesion and proliferation (124). Another composite
hydrogel (hyaluronic acid-agarose) developed by Zhang et al. exhibited potential for
wound healing (125).
To overcome these limitations, agarose can be chemically functionalized or combined with
other polysaccharides (122, 124, 125). Gómez-Mascaraque et al. developed a hydrogel
(chitosan/agarose) that allowed cell adhesion and proliferation (122, 124, 125). Zhang and
collaborators combined hyaluronic acid with agarose and produced a hydrogel that
revealed a great potential to improve the wound healing (125).

46

OH
O

OH
O

OH

H

O

O

OH O

OH

n
Figure 1.7 Structure of Agarose

1.7 Statement of Purpose
Several NO releasing polymer systems have been reported in the literature with promising
results for potential biomedical and pharmaceutical applications. Despite their potential
benefits, none of the NO releasing material reported to date have been clinically applied.
Some of the main problems with these materials are: 1) short durations of NO release 2)
production of toxic byproducts 3) instability of the NO donor during storage 4) poor dosage
control 5) exorbitant cost of NO donor, and 6) lack of efficient local and systemic delivery.
The purpose of developing NO delivering polymer system, particularly in wound healing,
is to mimic the antimicrobial role of NO released by the macrophages, endothelial cells
and other cells. For this purpose, it is extremely crucial to develop materials which can
deliver similar physiologically relevant levels of NO without risk of any toxic byproduct.
The primary purpose of this thesis research is to develop a simple, cost effective, novel
polymer system which can address some of the major challenges listed above. A double
emulsion solvent evaporation method was employed to produce poly (l-lactic) acid (PLLA)
microparticles encapsulating NO donor S-nitroso-N-acetylpenicillamine (SNAP). The
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resultant microparticles were shown to release NO in a controllable manner with photo
initiated. In the presence of copper (II) ions and ascorbate, the microparticles were shown
to have instantaneous NO release. Two distinct size of microparticles were produced using
two different stirring rates to study differences in their NO loading and NO release profile.
The SNAP loaded NO releasing microparticles were incorporated into a thermosensitive
chitosan-agarose hydrogel system. In wound healing, the hydrogel can provide a moist
environment in addition to promoting cell growth while NO releasing microparticles can
provide antibacterial effect. Therefore, the combination of hydrogel and NO releasing
microparticle was studied. The NO release profile of the hydrogel-microparticle composite
was studied. The composite was tested for NO release using photoinitiation. Another
chitosan-agarose hydrogel containing ascorbic acid was tested to initiate NO release from
this hydrogel-microparticle composite. This system may be beneficial for the treatment of
chronic wounds.
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2 Particle synthesis and characterization
2.1 Introduction
Nitric oxide (NO) is an important signaling agent present naturally in the body responsible
for a variety of biological functions such as controlling hemostasis, regulating vascular
tone, encouraging revascularization and fight infection (1). NO is also involved in
physiological processes such as anti-inflammation (2) and wound healing (3, 4). The
pharmaceutical application of NO is complex because of its short life, high reactivity and
short diffusional distance (5). The therapeutic application of gaseous NO (gNO) is very
complicated and expensive. Therefore, a stable NO storage material in the form of a wide
range of NO donor molecules such as nitrites, S-nitroso (RSNO) compounds and
diazeniumdiolates (NONOates) (4, 6, 7) have been studied for NO delivery. Several studies
have attempted to the use NO donors by blending or covalently attaching them to the
biodegradable materials for controlled delivery of tunable levels of NO. Coneski et al.
synthesized the NO releasing functionalized polyesters which delivered NO in the range of
0.0-2.28 μmol (8).
NONOates and nitrosothiols (RSNOs) are the two most promising groups of small
molecules NO donors recently studied for the delivery of NO (9). Ameer group developed
another class of NO releasing biodegradable polyesters which are two different variations
of diazeniumdiolated poly (diol-citrate) elastomers. In the first report Zhao et al.
synthesized and characterized the first variation of elastomer film which released NO over
a period of 3 days and has a degradation rate of 20% over 6 weeks (10). In the second
report, Wang et al. employed the photo-crosslinking method to the elastomer system which
augmented the NO release time to 7 days while reducing the degradation rate to between
26-32% over 6 months (11).
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Pulfer et al. prepared polyethylenimine microsphere derivatized with a NONOate moiety.
These microspheres have a diameter of 10-50 μm with a release of 194 nmol NO/mg and
a half-life of 66 h under physiological conditions (12). In another study, a small molecule
donor diazeniumdiolated proline (PROLI/NO) was encapsulated within biodegradable
PLGA and polyethylene oxide-co-lactic acid (PELA) microspheres by Jeh et al. for
delivery of NO (13). Zhang et al., produced fumed silica particles by first tethering
alkylamines onto the surface of silica and then these amine groups were converted to
corresponding N-diazeniumdiolate groups via reaction with NO gas at high pressure which
produced NO for few hours (14). Schoenfisch’s group synthesized gold (15), silica
nanoparticles (16) and polypropylenimine dendrimers (17) which were functionalized with
NONOate moieties released NO for several hours. The same group also developed O2protected diazeniumdiolate-modified mesoporous silica nanoparticles which had the
longest NO release time with a half-life of 3 weeks at pH 7.4 (18). Diethylenetriamine
(DETA) NONOate was successfully encapsulated into poly (lactic-co-glycolic acid)
(PLGA) microparticles using solvent evaporation method by Yoo et al. The Deta nonoate
loaded PLGA microparticles released ~0.3 μmol NO/mg polymer in a controlled manner
for just over 6 h (19). Similarly, Nurhasni et al. developed NO releasing poly(lactic-coglycolic acid)-polyethylenimine (PEI)/ diazeniumdiolate nanoparticles (NO/PPNPs) with
an average size of 162 ± 19 nm for antibacterial and wound healing activity (20). The PEI
was selected as the NO donor polymer. The synthesized PEI/diazeniumdiolate
(PEI/NONOate) was incorporated in to PLGA nanoparticles resulting in NO release
capacity of 1.4 μmol NO/mg of polymer with a release lifetime of over 6 days. The main
drawback of these particles in general is possibility of formation of carcinogenic Nnitrosamines as a side product during the production of N-diazeniumdiolates using
polyamine compounds (21).
Another NO donor employed for storage and delivery of NO is S nitrosothiol (RSNO)
which are endogenously produced in vivo and are non-toxic. Several mechanisms such as
heat, light, exposure to copper and ascorbic acid triggers their decomposition and release
NO (22-24).
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The different RSNO decomposition mechanisms are useful for their bio applications as in
vivo body conditions can stimulate the NO release from RSNOs. Researchers have utilized
S-nitrosothiols as NO donor within polymer systems. Gierke et al. synthesized a silicon
rubber material in which SNAP was covalently linked to polydimethylsiloxane (SNAPPDMS). This material released NO via light trigger (25). Brisbois et al. investigated and
found two low water uptake biomedical grade polymers Elast-eon E2As and CarboSil
have potential to control the release of NO from the SNAP. When doped within these
polymers, SNAP is exceptionally stable within them and can release NO up to 3 weeks at
physiological conditions (26, 27). In another study, Wo et al. demonstrated that long term
NO release can be achieved from carbosil-SNAP because of slow crystal dissolution
process as SNAP concentration in carbosil when exceeds its solubility makes the SNAP
present in carbosil in crystalline form. The hydrophobicity of the carbosil polymer and
stabilization of crystalline SNAP by intermolecular hydrogen bonds limits the water
diffusion only to the polymer surface which keeps this composite stable during storage for
at least 8 months (28, 29).
Frost et al. anchored RSNOs to fumed silica particles with a NO loading of 21-138
nmol/mg and blended into polyurethane and silicone rubber matrixes to create films that
release NO at controlled rates. The formed films embedded with particles were capable of
NO release when exposed to copper(II) ions or ascorbic acid or upon shining light (30). A
RSNO modified polyamidoamine (PAMAM) dendrimer was developed by Stasko et al.,
which can store up to 2 μmol NO per mg of dendrimer. They can release NO for 10 min to
several hours via copper(II) and light exposure (31). These types of particles have an issue
as the NO donors in these systems are immobilized on the surface exposed to the matrix
environment. The presence of even tiny amounts of copper or ascorbate ions can induce
burst release which is a problematic effect. Lautner et al. encapsulated SNAP into PLGA
(RG 503H and RG 504) microspheres using solid-oil-in water (S/O/W) emulsion method.
The microspheres were 20-125 µm in size and exhibited controlled localized NO release
from PLGA RG 504 in the presence of copper(II) and ascorbate (32).
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The aim of this study was to develop a microparticle based NO delivery system that could
provide physiologically relevant levels of NO for proper wound healing without yielding
any toxic by-product. The NO donor used in this study i.e. S-nitroso-N-acetyl-Dpenicillamine (SNAP) breaks down into N-acetyl-L-penicillamine (NAC) after the loss of
NO which is non-toxic at low levels (33). Even after the loss of acetate group from the
NAC, the product penicillamine itself is FDA approved for reversing heavy metal ion
poisoning (34).Herein, PLLA microparticles encapsulated with S-nitroso-N-acetyl-Dpenicillamine (SNAP) have been developed for efficiently delivery of NO. PLLA
microparticles were prepared using double emulsion method at two different stirring
speeds. The size, morphology, and encapsulation efficiency of these microparticles were
evaluated. The controlled NO release profile of SNAP loaded microparticles was assessed
using light activated release. The total amount of NO released via combination of light,
copper (II) and ascorbate ion was also explored.

2.2 Material and method
2.2.1

Materials

Microparticles were prepared using biodegradable poly (l-lactide) acid (PLLA) granules
purchased from NatureWorks LLC (Blair, NE, USA). Emulsifying agent poly vinyl alcohol
(PVA) with molecular weight of 9,000-10,000 80% hydrolyzed was purchased from
Aldrich (St. Louis, MO, USA). Chelator for transition metal ion Chelex® 100 resin (100200 mesh, sodium form) and Cyclam (1, 4, 8, 11-tetraazacyclotetradecane) were obtained
from Bio-Rad (Hercules, CA, USA) and Acros Organics (Geel, Belgium) respectively. L(+)-Ascorbic Acid used for experiments was purchased from J.T Baker (>= 99.5 %)
(Center Valley, PA, USA). Copper chloride (CuCl2) anhydrous was purchased from Alfa
Aesar (Haverhill, MA). DMSO and Dichloromethane were obtained from Sigma-Aldrich
(St. Louis, MO, USA). For stirring emulsion, air stirrer (Model no. A) with a speed ranging
from rpm 200 ‑ 10,000 and air input pressure ranging from 30 -100 psi was purchased
from Arrow Engineering Co. (Pennsylvania, N.J., USA).
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2.2.2

SNAP synthesis

N-acetyl-D-penicillamine, and sodium nitrite (99.999% trace metals basis) were obtained
from Sigma-Aldrich (St. Louis, MO, USA). For the synthesis of S-nitroso-Nacetylpenicillamine (SNAP) crystals, 200 mg of N-acetylpenicillamine (NAP) was
dissolved in 5 ml methanol and sonicated for 5 mins. The solution was acidified by slowly
adding two milliliters of 1M HCl and 100μl of concentrated H2SO4. Then 144.9 mg NaNO2
were added to the acidified NAP solution and vortex mixed till all the sodium nitrite was
dissolved avoiding light. A dark green/red color in the SNAP solution gradually developed
and the solution was ice cooled for 45 min. After cooling, the methanol in the SNAP
solution was evaporated by rotary evaporation and SNAP crystals were collected using
vacuum filtration. The crystals were washed thrice by diH2O repeatedly and air-dried. The
SNAP crystals were kept in refrigerator 4℃ in dark until further use.
2.2.3

S-nitroso-N-acetylpenicillamine (SNAP) loaded poly (l-lactic) – polyvinyl
alcohol microparticles

2.2.3.1 Preparation of SNAP loaded microparticles
Biodegradable SNAP loaded PLLA microparticles were prepared using water-in-oil-water
(W/O/W) solvent evaporation method. This method was chosen over much simpler waterin-oil solvent evaporation because S-nitroso-N-acetylpenicillamine (SNAP) is insoluble in
dichloromethane and partially soluble in water which can lead to drug loss during
preparation method. S-nitroso-N-acetylpenicillamine (SNAP) was dissolved in dimethyl
sulfoxide (DMSO) as it is completely soluble in DMSO.
The schematic representation of the snap-loaded microparticle production is shown in Fig
2.1. First, 20% (w/w) PLLA polymer solution was prepared. For this, 200 mg of poly (llactic acid) (PLLA) was dissolved in 1 ml of dichloromethane (DCM) in a 20 ml disposable
scintillation vials. 10 mg cyclam (1, 4, 8, 11-tetraazacyclotetradecane) were added to the
polymer solution to bind any copper ion present in the solution. Then, 20 mg of SNAP
were taken in an Eppendorf tube and dissolved in 100μl dimethyl sulfoxide (DMSO) and
vortex mixed. The SNAP solution was poured to the polymer solution and vortexed gently
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avoiding light. The polymer-SNAP solution was sonicated for 2 min in a bath sonicator.
This forms the primary (water in oil) emulsion which is green in color. In a beaker, 1%
(w/w) poly (vinyl) alcohol (PVA) was prepared as an emulsifier. For this, in a beaker 500
mg of PVA were dissolved in 50ml chelex containing 0.01M HCl using a magnetic stirrer.
Chelex is used as a chelator to bind any copper ion in the diH2O. Chelex when added to
diH2O raise the pH and make it basic. HCl was added to the PVA emulsifying solution to
prevent decomposition of SNAP at a basic pH as SNAP is stable at acidic pH levels. The
primary solution was then introduced dropwise to aqueous 1% PVA solution containing
0.01M HCl to form water in oil in water (W/O/W) emulsion. The final emulsion was stirred
using air stirrer at two different speeds 500 rpm and 2500 rpm at 25 °C for 3 h in a fume
hood to remove organic solvent. While stirring, the final solution was kept in an ice bath
to prevent thermal decomposition of SNAP. The microparticles were collected by
centrifuge at 2000 RPM and then recovered by washing three times with chelex treated
diH2O. The microparticles were air dried for 24-48 h and stored at −20°C until further
usage.

Figure 2.1 Preparation of the microparticles using double emulsion solvent evaporation
method. Produced microparticles were collected, air dried and stored in dark at -20 ℃.
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2.2.4

Yield of the prepared microparticles

Yield of the microparticles prepared by double emulsion was calculated to evaluate the
effectiveness of the method. It is calculated using equation:
Yield = W (microparticles)
W (total)

(1)

W (microparticle) is the weight of the produced microparticles
W (total) is the total weight of the polymers and the drug used to prepare microparticles
2.2.5

Characterization of the SNAP loaded microparticles

The morphology, size and size distribution of the SNAP loaded and blank microparticles
both 500 and 2500 rpm were investigated by using scanning electron microscope (SEM)
with a Hitachi S-4700 field emission-scanning electron microscopy (FE-SEM). Samples
were prepared by mounting a small amount of microparticles to the two-sided carbon tape
on the top of the metallic sample holder. Then the samples were sputter coated with 5nm
of platinum-palladium (Pt/Pd) alloy with a current of 20mA using Cressington 208HR with
a MTM-20 film thickness monitor. Size distribution was determined by measuring the
diameters of microparticle population from SEM image using ImageJ software.
2.2.6

UV-Vis analysis of SNAP loaded microparticles

UV-Vis spectroscopy was used to determine the SNAP loading in the microparticles. To
determine the SNAP concentration in each batch of microparticles, 20mg of the
microparticles were dissolved in 2ml of 3:2 dichloromethane to methanol. The
concentration of SNAP was measured by measuring absorbance at 340 nm using UV-Vis
(Perkin Elmer Lambda 35 spectrometer (Waltham, MA). The absorbance coefficient of
SNAP was calculated by taking absorbance of different concentration of pure SNAP in
dichloromethane: methanol solution.
Encapsulation Efficiency = (Actual Loading *100)/ Theoretical Loading)
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(2)

Where, actual loading = (weight of SNAP in analyzed microparticles*100)/weight of
microparticles used in UV-Vis analyses
Theoretical loading = (weight of SNAP added in microparticles*100)/weight of polymer
and SNAP added during the preparation
2.2.7

In vitro nitric oxide release study of SNAP loaded microparticles using Nitric
Oxide Analyzer

The NO release measurements were quantified using ozone based chemiluminescence
detection with a Sievers 280i Nitric Oxide Analyzer (NOA) (GE Instruments, Boulder, CO,
USA) using 200 ml/min flow rate, with both house nitrogen as the sweep gas. The
instrument was calibrated with Zero NO gas and 45 PPM standard calibration NO (Air
Liquid Healthcare America Corp. Plumsteadville, PA). Nitrogen was used as a sweep gas
for carrying NO into NOA.
2.2.7.1 Controlled NO release analysis
For controlled light-initiated NO release measurements, 5mg SNAP loaded microparticles
were placed in an amber vial and illuminated with different light intensity from a 470 nm
LED (VAOL-5GSBY4, Mouser electric, Mansfield, TX) using variable voltage (3V, 4.5V,
6V, 7.5V, 9V, 12V). The NO release was measured for 2 min at each voltage first
increasing and then decreasing.
2.2.7.2 Total NO release analysis
For total NO release, 5mg of microparticles were placed in amber vial with a magnetic stir
bar attached to the LED source. 0.5 ml solution of 50 μM CuCl2 and 100 mM ascorbic acid
was added to the microparticles after a plateau was reached in the detected NO
concentration, which is usually 15 min. Along with the CuCl2 and ascorbic acid solution,
microparticles were illuminated with same LED light at 4V.
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Both NO release experiments were performed at room temperature. The NO levels in ppb
unit were converted to moles sec-1 mg−1 unit using the NOA instrument constant that was
determined by quantitative reduction of a known quantity of nitrite. Integration of NO
release curves for given period was done to calculate the amount of NO released in both
experiments.
2.2.8

Statistical analysis

The statistical analysis of the data was done using MS-excel 2016. All the data were shown
as the means (±SD). Two-tailed homoscedastic student’s t-test was used to statistically
analyze the data. The p value (<0.05) was considered significant. The graphs were made
using the GraphPad Prism version 7.00 for Windows, GraphPad Software (La Jolla,
California, USA) (www.graphpad.com).

2.3 Results
2.3.1

SNAP loaded PLLA microparticles

SNAP loaded microparticles were successfully prepared using w/o/w double emulsion
method with air driven stirrer by air engineering co. (Pennsylvania, N.J.) at varying stirrer
speed parameter. In this study PLLA polymer was used for encapsulation of SNAP which
is a slow degrading polymer. The double emulsion system was used because the PLLA
polymer dissolves in methylene chloride but the NO donor SNAP does not. In this study,
DMSO was used to encapsulate as an inner aqueous solvent for dissolving SNAP. In this
study, microparticles prepared at stirring rate of 500RPM and 2500RPM are denoted as
microparticles(500) and microparticles(2500).
2.3.2

Yield of the microparticles

Yield of the microparticle was calculated to evaluate the effectiveness of the preparation
method. Yield of microparticles produced at both the stirring speeds were calculated
using equation number 1. Results and standard deviations are reported in the table 1.
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Table 1 Yield of produced microparticles
Composition
SNAP-PLLA Microparticles (500)

yield (%) ± s.d.
61.78 ± 5.4

1B

3B

SNAP-PLLA Microparticles (2500)

54.4 ± 4

5B

There is no significant difference (p=0.133) in the yield of microparticles produced at
different speeds.
2.3.3

Characterization of microparticles

2.3.3.1 Size and morphology of SNAP loaded microparticles
Microparticles produced looks like white powder when visually observed. For more precise
observations scanning electron microscope (SEM) was employed. Observed microparticles
showed cluster formation and smaller particles adhered to larger particles. On visual
observation, smaller microparticles (<150 µm approx.) appear to be spherical without any
irregularities. On the other hand, larger microparticles (>150 µm approx.) appear to have
irregular appearance and show either fully collapsed structured or pits on the surface of the
microparticles. The SNAP loaded microparticles have smooth surface topography with
visible pores which can be observed in fig 3.1 (d), (f), (h) and fig 3.2 (l), (n), (p). The blank
microparticles, consisting of only PLLA however, have a rough surface with visible pores
fig 3.1 (b) and fig 3.2 (j). Irregularities can be seen on the surface of the larger
microparticles denoted by asterisk (*).
Size distribution of SNAP loaded PLLA microparticles was measured using image J
analysis tool and at least 150 microparticles were measured for each picture. The
microparticles prepared at different speed (500 RPM and 2500 RPM) showed significant
difference (p=0.02) in size. The average size measured of the SNAP loaded microparticles
prepared at 500 RPM stirring rate was 256.7 ± 11.7 µm while microparticles at 2500 RPM
were 207.4 ± 19.7 µm. The blank microparticles, surprisingly, showed a smaller size
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compared to the SNAP loaded microparticles for both stirring speeds. Most of the
microparticles were in the range of ~100-300 µM with some below 100 µm and some
above 300 µm.
It has to be emphasized that size measuring method here may not be accurate. It is possible
to use tools that can be used for accurate diameter measurements from SEM images and
the from size distribution of the sample. For these accurate measurements, the sample has
to be prepared as a monolayer of the separated microparticles. Microparticles may be in
different focus planes due to three-dimensional cluster formation which can affect the
diameter measurements as some microparticles may be either near or farther behind
microscope. For this analysis, oval and elliptical tool of the ImageJ software was used to
measure every single microparticle by hand. Scale was set to match the scale bar of each
SEM image. This method of measuring diameter of microparticles along with the image
quality may cause significant inaccuracy to the result. Therefore, microparticle size
distribution has to be considered approximate.
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2.3.3.2 SEM images
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Figure 2.2 SEM images of microparticles made at 500 RPM (a), (c), (e), (g) shows the
blank microparticle and SNAP loaded microparticle I, II, III respectively at magnification
1.00mm. (b), (d), (f), (h) surface topography of blank microparticle and SNAP loaded
microparticle I, II, III respectively.
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Figure 2.3 SEM images of microparticles made at 2500 RPM (i), (k), (m), (o) shows the
blank microparticle and SNAP loaded microparticle I, II, III respectively at magnification
1.00mm. (j), (l), (n), (p) surface topography of blank microparticle and SNAP loaded
microparticle I, II, III respectively.
2.3.4

Encapsulation efficiency of the SNAP loaded microparticles

2.3.4.1 UV- Vis analysis of SNAP loaded microparticles
The SNAP loading of the PLLA microparticles were determined by UV/VIS absorption
after dissolving the microparticles in DCM: methanol (3:2). The molar absorptivity of
SNAP in DCM: methanol was determined by making standard curve of SNAP (Fig. 3.3)
which was calculated by taking absorbance of dissolved SNAP in DCM: methanol at
different concentrations.
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Standard curve of SNAP in DCM:Methanol (3:2)
1.0

Abs.= 0.5 x conc.
R2= 0.9943
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Figure 2.4 Standard curve of SNAP in DCM: Methanol (3:2)
The UV-Vis analysis of the SNAP loaded microparticles(500) and SNAP loaded
microparticles(2500) are shown below in Fig. 3.4 and Fig. 3.5. The molar absorptivity of
SNAP in DCM: methanol at 340 nm was determined as εSNAP= 500 M-1 cm1. The
characteristic absorbance of SNAP at 340 correlated to the π→π* electronic transitions
of the S-NO functional group.
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Figure 2.5 UV-vis analysis of SNAP loaded microparticles(500) (n=3)
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Figure 2.6 UV-vis analysis of SNAP loaded microparticles(2500) (n=3)
The double emulsion method (W/O/W) yielded PLLA microparticles encapsulating SNAP
an encapsulation efficiency of ~35% for microparticle(500) and ~33% for microparticles(2500)
(see Table 2). There was no significant difference (p=0.54) in the encapsulation efficiency
between the PLLA microparticle(500) and PLLA microparticles(2500). The amount of
encapsulated SNAP was approximately 0.13–0.17 μmol per mg microsphere.
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Table 2 Composition (W/O/W), stirring speed, loadings, and particle size distribution and
encapsulation efficiency
Composition Stirring SNAP
particle
size Loading
Encapsulation
speed
amount (µm)
(w/w)%
efficiency (%)
(RPM)
(mg)
Blank-PLLA
500
0
190 ± 21.3*
n.a
n.a
microparticle
SNAP-PLLA
500
20
256 ± 11.7** 3.2 ± 0.51
35.2 ± 5.6
Microparticle
Blank-PLLA
2500
0
130* ± 69.7*
n.a
n.a
microparticle
SNAP-PLLA
2500
20
207 ± 19.7**
3.0 ± 0.13
33.0 ± 1.4
Microparticle

* Standard deviation of different microparticle size in a single batch of microparticles (n=1)
** Standard deviation of different microparticle size in three different batches of microparticles
(n=3)

2.3.5 In vitro NO release profile study of SNAP loaded microparticles
2.3.5.1 Controlled NO release study via Light
For in vitro monitoring of NO release from the microparticles, an amber vial was employed
to contain the microparticles to avoid light induced NO photo-release. NO donor SNAP is
sensitive to light which can release NO in a highly controllable manner. When SNAP is
encapsulated in PLLA microparticles, photoinitiation of SNAP-PLLA microparticles was
done to evaluate controlled NO release from them. LED light was applied to the
microparticles to trigger the NO release. The SNAP loaded PLLA microparticles in dry
powdered form when irradiated with light with a varying intensity. The microparticles
showed a linear response with varying light intensities. Fig 6. (A), (B) demonstrates that
the NO release was controlled by altering the drive voltage applied to the LED, thus
changing the intensity of light produced by LED.
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In the absence of light, virtually no nitric oxide was released (trace a). However, as the
light incident on SNAP microparticles is turned on and the light intensity is increased by
stepping through 0, 3, 4.5, 6, 7.5, 9 and 12 V of applied potential (traces a, b, c, d, e, f and
g), the NO release increases. The produced NO was purged out from the vial with a
continuous N2 stream which is detected by the gold standard for NO release measurements
that is chemiluminescence method. The voltage was kept 0V usually for 15 mins to
measure the NO concentration of the purged gas until a plateau reached in NO detection.
The light intensity was kept constant for exact 2 mins at every voltage point and then
decreased in the same manner. The SNAP loaded microparticles show an immense
potential as a controlled NO-releasing material. This shows that light can be used as an
external stimulus to trigger NO release which allows precise control of turning on and off
mechanism for increasing and decreasing NO flux. This can provide an accurate amount
of NO levels required to achieve specific physiological responses such as wound healing.
NO release from both SNAP-PLLA microparticle(500) and SNAP-PLLA microparticles(2500)
was studied using this light method.
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Figure 2.7 (A) Representative curve shows the controlled NO release from microparticle(500). In the figures, trace (a)
shows zero NO release in absence of light. (b) to (g) shows increasing and then decreasing NO release with varying
intensity of light at changing voltage
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Figure 3.6 (B) Representative curve shows the controlled NO release from microparticle(2500). In the figures, trace (a)
shows zero NO release in absence of light. (b) to (g) shows increasing and then decreasing NO release with varying
intensity of light at changing voltage

2.3.5.2 Effect of particle size on the light initiated controlled NO release between
microparticles
In this study, when the amount of NO released from the microparticle(500) and
microparticle(2500) via light were compared, it did not show any significant difference
(p=0.67) between the two. The NO release from inside the microparticles through SNAP
decomposition occurs mainly through the diffusion. This determines that the amount of
NO release depends on the surface area of the microparticles the light has been shined
upon. The particles with bigger surface area should release more NO compared to the
particles with smaller surface area. However, according to the Fig. 3.7, no significant
difference (p=0.67) has been observed between both microparticles. This may infer that
either controlled NO release via light over a given period of time does not depend on the
surface area of the microparticle or the size difference between both the microparticles is
not significant enough to produce significantly different NO amounts.
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Figure 2.8 Comparison of controlled light initiated NO release from microparticles(500) and
microparticles(2500)
2.3.6

Total NO release study via light, Copper (II) ions and ascorbate

Total NO means the overall amount of NO that can be released or available for release
from the SNAP encapsulated in the PLLA microparticles. Total NO release measurements
were done using all the triggers responsible for NO production from SNAP. This includes
light (photo initiation) using LED, copper (II) ions and ascorbic acid. The NO release
measurements were done at room temperature. In Fig. 3.8 (a) and (b), the microspheres
were shown to release NO in the presence of 50µM CuCl2 and 100mM ascorbic acid which
are SNAP decomposition initiators. In the experimental setup during NO detection, after
reaching a plateau by purging out the released NO for 15 mins, 0.5 ml of 50µM CuCl2 and
100mM ascorbic acid was added to the vial using a syringe which showed an instantaneous
release of NO from microparticles. LED light was turned on at 4V which acts as an
additional factor in NO release. The SNAP-PLLA microparticle showed to follow biphasic
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NO release profile that is an initial burst release and then a slower release period, which is
typical for PLGA drug delivery devices (DDDs).

Figure 2.9 Total NO release from the (a) microparticle(500) (b) microparticles(2500) using
light (4V), 50µM CuCl2 and 100mM ascorbic acid
As shown above, in this study, drug release profile reveals initial burst followed by slower
release period. During the initial burst period that ensues over the first two hours,
approximately 42.1% ± 7.6 and 39.2% ± 14.8 of total NO measured is released from the
SNAP-PLLA microparticle(500) and SNAP-PLLA microparticles(2500) respectively. After
the burst release, the drug is released more slowly over next several hours. The
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microparticle(500) and microparticles(2500) showed uninterred NO release for over 9 hours
and 13 hours respectively as seen in Fig. 3.9. After that time, the copper (II) ions in the
solution probably got exhausted and another 0.5ml of 50µM CuCl2 and 100mM ascorbic
acid was added to check more NO release. It was observed that only light was not enough
for further release which may be due to not enough penetration of light into the
microparticles. Both microparticles showed extended NO release for approximately 2
hours before stopping more NO release. Addition of another 0.5ml of 50µM CuCl2 and
100mM ascorbic acid did not cause any more NO release which showed no more
possibility of NO production from the used microparticles.

Figure 2.10 comparison of NO release rate from the microparticle(500) and
microparticles(2500)
2.3.6.1 Effect of particle size on total NO release between microparticles
As shown in the fig. 3.10 below, using the student’s two tail t-test, the comparison of the
total amount of NO produced between the microparticle(500) and microparticle(2500)
exhibited a statistically significant difference (p=0.03) in the NO released from both
particles. This can infer that particle size affects the amount of release from the particles.
The nitric oxide release rate from the microparticle(2500) is also higher compared to
microparticle(500) as seen in fig 3.9 above. It is strange to observe more total NO release in
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microparticle(2500) compared to microparticle(500) as both have shown almost similar
encapsulation efficiency of SNAP. The reason for this can be either easy availability of
more encapsulated SNAP in smaller particles (microparticle(2500)) or non-availability of
some amount of encapsulated SNAP in bigger particles (microparticle(500)). A difference

Nitric oxide released (moles/mg)

in NO production quantities due to difference in particle size can be clearly observed.
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2.4 Discussion
SNAP (S-Nitroso-N-acetylpenicillamine) loaded PLLA microparticles were prepared
using double emulsion (water-in-oil-in -water) emulsion solvent evaporation method. The
microparticle system was developed and investigated as a possible nitric oxide delivery
system for wound healing application.
2.4.1

Size and characteristic of microparticle

SEM image analysis of the microparticles revealed smooth but irregular shape of the
microparticles. The microparticles were expected to have a spherical structure but most of
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them especially larger ones had depressions in them. They may have been formed during
the air drying process, but changes due to their exposure to the electron beam during SEM
imaging is also possible (35). The average size of microparticles(500) (256 ± 11.7 µm) and
microparticles(2500) (207 ± 19.7 µm) was large which can be due to low force and shear
required to make them smaller as stirring rate was kept low. Also, homogenization was not
done in this method which may be reason for the larger size. The structure underneath the
surface may be dense, porous or hollow but any conclusion on the inner structure of
microparticles based on these pictures cannot be made. SEM pictures of these same
microparticles after full drug release would have been interesting. Many factors that affect
the structure of the microparticles but the most important probably is the preparation
method (36). Here, water-in-oil-in-water (w/o/w) double emulsion solvent evaporation
method is used. In double emulsion process, solvent evaporation significantly affects the
structure of the formed particles. Solvent evaporation rate influences the inner structure of
the microparticle. Porous structure can collapse easily than dense structure causing early
degradation of matrix (37).
2.4.2

Encapsulation efficiency based on total NO release

Although encapsulation efficiency was calculated using UV-vis spectroscopy. We also
calculated encapsulation efficiency based on total NO release analysis. As reported above,
overall amount of NO released by the microparticles was less than the calculated
encapsulated efficiency. UV-vis results showed almost equal encapsulation efficiency for
both microparticles(500) and microparticles(2500). However, based on total NO release
analysis, a difference in encapsulation efficiency was observed with microparticles(2500)
showing higher encapsulation than microparticles(500). This can be due to significant
difference (p=0.02) in microparticle sizes.
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Table 3 Comparison of average total nitric oxide release and encapsulation efficiency
from SNAP-PLLA microparticle(500) and SNAP-PLLA microparticle(2500)
Composition

Average total NO release ± s.d.

Encapsulation efficiency (%)

SNAP-PLLA
microparticle(500)

6.11 ± 1.71 x 10-8

14.79% ± 4.14

8.43 ± 2.92 x 10-8

23.25% ± 2.14

SNAP-PLLA
microparticle(2500)

There could be another reason for this difference in overall NO release even though no
difference was shown in encapsulation efficiency using UV-vis. This could be due to
possible bonding of SNAP to the PLLA polymer through hydrogen bond. It is possible that
SNAP is more closely bound to PLLA in larger microparticles compared to smaller ones.

Figure 2.12 Possible mechanism of SNAP bonding to PLLA by hydrogen bond.
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2.4.3

Low encapsulation efficiency

The drug encapsulation efficiency is an essential factor in drug delivering device as it
determines how much drug can be loaded and released. As the double emulsion solvent
evaporation was used in this study, constituting two major phases- dispersed phase (an
inner aqueous phase containing the drug (SNAP) and polymer organic phase) and
continuous phase (emulsifier containing aqueous phase). The NO donor SNAP used in this
study is hydrophilic which causes its diffusion in to the continuous phase from the
dispersed phase resulting in low encapsulation efficiency. To prevent this, double emulsion
method was used as it prevents the escape of SNAP from dispersed phase in to the
continuous phase by first formation of primary emulsion. However, still some loss of
SNAP occurred. The SNAP also degrades due to the presence of even traces of metal ions
especially copper. The Cu metal ions were chelated using metal chelators chelex and
cyclam to prevent unwanted NO release due to decomposition of SNAP by Cu+.
Additionally, SNAP is stable at acidic pH (38). Thus, the pH of the continuous phase plays
an important role in stabilizing the drug to be encapsulated which in turn can increases its
encapsulation in the microparticle (19). The continuous phase which is PVA in water turns
basic due to chelex addition. It is acidified by adding HCl. This helps in preventing SNAP
degradation in the developing microparticles while preparation. However, even after taking
such steps, the encapsulation efficiency was low. There can be several reasons for low
encapsulation efficiency such as low polymer concentration, high dispersed phase to
continuous phase ration and slow solvent removal rate (39). The SNAP in this study was
first dissolved in DMSO (dimethyl sulfoxide) during formation of primary emulsion as
solubility of SNAP in DMSO is higher than water. The DMSO could have caused SNAP
degradation or its inability to form a stable primary emulsion could be reason for low
encapsulation.
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2.4.4

NO release profile and burst release

In vitro drug release profile from the SNAP loaded microparticles followed a bi-phasic
release profile that is initial burst release within few hours followed by slower release
phase. This is a characteristic of PLA microparticles particularly with small dimeter (4042). Burst release is a fast release phase in the beginning of the release period. There are
several reasons for fast NO release from the microparticles. The amount of NO which is
released in this study during the burst release could include non-encapsulated SNAP,
SNAP located near the surface as well as SNAP adhered to the surface of microparticles.
Although during the processing, the microparticles were washed to remove unencapsulated
SNAP, some amount can remain in the final product. The most important factor affecting
the properties of microparticles is the preparation method (36). We cannot directly compare
the microparticles prepared in this study with microspheres prepared by Lautner et al.
because of different preparation methods themselves affects microparticle properties.
Parameters such as polymer concentration, ratio of dispersed to continuous phase in the
emulsion preparation phase poses challenges to microparticle preparation can all influence
properties of microparticles. in the literature, the microspheres made using solid-in-wateroil emulsion solvent evaporation method with free acid terminated PLGA polymer (RG
503H) showed NO release for typically 10–14 days while 30 days in case of ester capped
terminus PLGA (RG 504) microspheres (32). The diameter of those microspheres was in
the range of 50-60 µm. The average size of particles i.e. microparticles(500) (256.7 ± 11.7
µm) and microparticles(2500) (207.4 ± 19.7 µm) in our study are comparatively very large.
Also, in this study, PLLA polymer was used for NO delivery not PLGA as degradation rate
of PLLA is expected to be much slower due to absence of glycolic acid in the matrix.
The second reason can be size of the microparticles. Diffusion is a crucial factor in drug
release from polymeric microparticles. Usually when the size of the drug delivery device
(microparticle) increases, diffusion pathway becomes longer which in turn slows drug
release (43). Smaller microparticles would have a high surface area: volume ratio and
shorter diffusion distance that allows more rapid release. However, drug distribution within
polymer matrix is also affected by microparticle size (41) which is the third reason that is
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heterogeneous drug distribution. Drug release profile is affected by the location of the drug
in the microparticle. The main reason for burst release is surface associated drug (39). The
method used in this study should enable the homogenous drug distribution in polymer
matrix as drug and polymer are completely dissolved into the solvent. Therefore, drug
release becomes faster with a decrease in diameter of microparticles as well as also
indirectly affected by increased partitioning of the drug to the surface with increasing size
and more rapid polymer degradation in larger microparticles. Interestingly, in this study
microparticles have larger diameters and wider size distribution. Drug release period
became

longer

when

the

diameter

was

decreased

(diametermicroparticle(2500) <

diametermicroparticle(500)). So, that means if the SNAP portions towards the surface, then the
diffusion distance decreases in larger microparticles which expects to increase NO release
rate. The effect of diffusion due to size is superimposed by the effect of the drug
distribution. Along with this, increased degradation rate of larger microparticles can also
slightly increase release rate.
Fourth probable reason is inner porosity. As described earlier, the preparation method
affects the structure of the microparticles. There are contrast in literature about effect of
solvent evaporation rate. According to some, the faster solvent evaporation rate means
more porous structure of the microparticles (36, 44). While some show that in solvent
evaporation method, more porous structure formed due to diffusion of aqueous phase in to
dispersed phase cause by low solvent evaporation rate (39). Porous matrix has faster drug
release rate compared to dense matrix microparticles. Fifth reason can be polymer-polymer
interactions. In this study, PVA has been as an emulsifier which many affect the drug
release properties of the microparticles. PVA may form a layer around formed
microparticles catalyzing degradation as it can act as a barrier to prevent diffusion of acidic
degradation product of PLA out from the microparticles (45). Low molecular weight drugs
are likely to have burst release profiles because of their small size (46). Nitric oxide is a
small molecule which can be the reason for burst release.
All this shows that, so many factors affect the drug release from biodegradable
microparticles as predicting the drug release is difficult. However, several methods exist
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to modify release profile such as coating microparticle with other more slowly degrading
polymer (47).

2.5 Summary
In this study, the PLLA microparticles encapsulated with NO donor SNAP were prepared
using double emulsion solvent evaporation (W/O/W). The microparticles of varied sizes
(microparticle(500) and microparticle(2500)) were prepared using different stirring speeds.
Considering all the experimental data collected, these PLLA microparticles encapsulating
SNAP were shown to release nitric oxide in a controllable manner on exposure to the light.
At different light intensities, SNAP-PLLA microparticles were shown to release different
amount of nitric oxide. The SNAP-PLLA microparticles were also experimentally tested
to show NO release in the presence of copper (II) and ascorbate. The microparticle(500)
demonstrated an average total NO release of 6.11 ± 1.71 x10-08 for 9 hours and
microparticle(2500) exhibited average total NO release of 8.43 ± 2.92 x10-08 for 13 hours.
These reported microparticles can be injected into the wound to accelerate healing or can
be incorporated into the hydrogel to be used as wound dressing.
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3 Particles in hydrogel system
3.1 Introduction
There is a need for developing new wound dressings which can improve wound healing
process, making it less painful and help in reconstructing the skin structure and function in
a brief period (1, 2). Among all the wound dressers introduced so far, hydrogels have been
crucial for skin regeneration because of their intrinsic properties which mimic the
extracellular matrix (ECM) and have the potential for cell proliferation, adhesion and
growth during tissue regeneration (3, 4). Hydrogels have high patient acceptability as they
aid in moist healing and provide coolness to the surface of the wound when applied to the
wound site leading to major pain reduction (5, 6).
As described above, NO is an important signaling molecule involved in many physiological
processes such as immune responses, wound healing, vascular and neurological functions
(7, 8). NO has short half-life, short diffusion distance and its therapeutic effects are dose,
duration and location dependent (9). Therefore, on demand controlled delivery biologically
active NO is very critical for any NO based effective therapies. Several hydrogels based
therapies have been studied by researchers to provide effective NO delivery. One of the
approach is β-galactosidase-mediated release of nitric oxide (NO) from hydrogels (10).
Zhao et al. covalently linked β-galactosidase-sensitive NO donors (β-gal-NONOate) to the
polymer backbone to develop an injectable chitosan hydrogel system (11). The enzymatic
activity of hydrogel β-galactosidase controls the NO release in micromolar concentrations
by hydrolyzing the glycosidic bonds. These materials exhibited no decomposition with
storage stability for over six months at room temperature. It was reported that local delivery
of NO by utilizing endogenous β-galactosidase activity lead to enhanced proliferation of
endothelial cells and angiogenesis stimulation in vivo. An enzyme mediated NO releasing
system lacks a fine control of dose and duration even though they demonstrate targeted NO
delivery on targeted sites. Hence, dosage control and delivery rate of NO are the main
challenges in developing NO based therapies.
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Three NO releasing hydrogels were synthesized by Bohl and West with two containing
diazeniumdiolate moieties and one with covalently linked S-nitrosothiol functionalities
(12). Polyethylene glycol N-hydroxysuccinimide monoacrylate (ACRL-PEG-NHS) was
reacted with poly-L-lysine to form a polyethylene glycol (PEG)-poly-L-lysine (PEG-Lys5NO) hydrogel. In this NO releasing hydrogel, the diazeniumdiolate was formed of free
amines of lysine residues followed by photocrosslinking with PEG-diacrylate. Another
hydrogel (PEG-DETA-NO) was prepared in equivalent manner with diethylenetriamine
(DETA) as an amine source formed by reacting with ACRL-PEG-NHS and
photocrosslinking. PEG-S-nitrosocysteine hydrogel was formed by reacting L-cysteine
with ACRL-PEG-NHS to form thiol-containing PEG species which were nitrosated in
nitrous acid and photopolymerized. These hydrogels showed sufficient NO release for
smooth muscle cell (SMC) growth inhibition and reduction in platelet adhesion. Shishido
et al. incorporated GSNO and S-nitroso-N-acetylcysteine (SNAC) into poly (ethylene
oxide)-poly (propylene oxide)-poly (ethylene oxide) (PEO-PPO-PEO) copolymer
hydrogel which showed slow NO release rate and prolong NO release lifetime of material
(13). An increase in blood flow indicating vasodilation of the underlying blood vessels was
observed when these materials were applied topically to the skin (14). Vercelino et al.
developed a S-nitrosoglutathione incorporated topical pluronic F127 hydrogel for treating
pain and impaired dermal blood flow (15). In another study by Schanuel et al.
functionalized PVA films with SNO groups and combined them with pluronic F127
hydrogel. The hydrogel layer prevents the burst release of NO from film and their
combination helps in accelerating wound contraction and inflammatory phase and decrease
wound gap (16). A thermosensitive Pluronic F68 branched with polyethylenimine (BPEI)
containing N-diazeniumdiolates (NONOates) was developed by Park et al. The developed
F68-BPEI-NONOates showed effective antibacterial activity with a good biocompatibility
and low cytotoxicity (17). A PEG based ointment incorporated with nitric oxide releasing
biocompatible Pluronic F127, branched polyethylenimine and 1-substituted diazen-1-ium1, 2-diolates was developed by Kang et al. The ointment demonstrated a slow NO release,
accelerated wound closure with heightened re-epithelialization, collagen deposition, and in
vivo blood vessel formation (18). Similarly, a thermosensitive Pluronic F127, branched
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polyethylenimine (BPEI), and diazeniumdiolates (NONOates) was developed as a novel
gel system. This F127-BPEI-NONOates system displayed increase in endothelial cell
proliferation and reduction of smooth muscle cell proliferation (19).
The Chitosan and agarose interactions permits the hydrogel production which is capable of
gelling because of polymer interactions within a desired target site. The combination
hydrogel of chitosan and agarose has shown to shown to influence neuron morphology,
help in neuron adhesion as well as enhance neural cell attachment and differentiation (20).
The hydrogel has also demonstrated an adequate wound healing environment by keeping
the wound moist and hydrated and preventing any bacterial infection (21). The hydrogel
exhibited to prevent water loss and wound dehydration and allowing adequate nutrient,
oxygen and carbon dioxide exchange at the wound site.
In this study, NO oxide releasing PLLA microparticles are incorporated in to a
thermosensitive deacetylated chitosan-agarose to explore their NO oxide releasing
capabilities. The wound healing and antibacterial properties of NO combined with the
gelling and wound dressing properties of chitosan-agarose hydrogel can be greatly
explored for appropriate wound healing.

3.2 Material and method
Low molecular weight chitosan (mol wt. 50,000-190,000 Da) was obtained from SigmaAldrich (St. Louis, MO). Agarose was purchased from SeaPrep (Seattle, WA). L- (+)Ascorbic Acid used for experiments was purchased from J.T Baker (>= 99.5 %) (Center
Valley, PA, USA).

3.2.1

Preparation of SNAP loaded microparticles and chitosan-agarose hydrogel
composite
Chitosan-agarose hydrogel was prepared using a simple procedure described by Cao et al
(20). The schematic representation of the production of chitosan-agarose hydrogel
embedded with snap-loaded microparticle is shown in Fig. 4.1. Briefly, 2% (w/w) chitosan
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(30 mg) was first dissolved to the 2.5% (v/v) acetic acid solution (50µl acetic acid in 1950
µl chelexed water). Chelex treated water was used to prevent any copper ion contamination.
5 mg of SNAP loaded microparticles were added to the chitosan solution. The chitosan
microparticle suspension was sonicated for 2 min and then magnetically stirred for an hour.
The chitosan-microparticles suspension was stirred to remove any microparticle
aggregates. Microparticles should be homogenously distributed when introduced into the
hydrogel. Agarose was then added to this suspension and dissolved by heating in a 60 ℃
water bath.
Polypropylene cylinders (1.2 cm diameter) were used as a mold to prepare the hydrogels.
After pouring the chitosan-agarose-microparticle solution in to the cut syringe, they were
covered with the parafilm to prevent any moisture evaporation and left at 4 °C for complete
gelation. Total gelation time depends on the volume of the hydrogel. Usually, this hydrogel
composition can gel within 20 min at 4 °C, however, large gels can take a longer time.
Therefore, the prepared hydrogels were left to gelate overnight. Blank hydrogels were also
prepared using the same method as the hydrogel microparticle composite. The blank
hydrogel is the hydrogel with same formulation as the composite gel without
microparticles.
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Figure 3.1 Preparation of microparticle incorporated chitosan-agarose hydrogel
3.2.2

Preparation of ascorbic acid chitosan-agarose composite hydrogel

Ascorbic acid loaded chitosan-agarose hydrogel was formulated using the same method as
described above. In this case, instead of microparticles, 100mM of ascorbic acid was added
to the chitosan-acetic acid solution and dissolved. To avoid possibility of NO release from
any copper ion present in water, chelexed water was used. NO Then agarose was added
and dissolved in a 60 ℃ water bath. This ascorbic acid composite hydrogel is poured in the
syringe mold and gelated overnight at 4 ℃.
3.2.3

In vitro nitric oxide release study of Hydrogel-microparticles using Nitric
Oxide Analyzer

The NO release measurements were quantified using an ozone based chemiluminescence
detection with Sievers 280i Nitric Oxide Analyzer (NOA) (GE Instruments, Boulder, CO)
using 200 ml/min flow rate, with both house nitrogen as the sweep gas. Nitrogen was used
as a sweep gas for carrying NO into NOA.
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Total NO release from hydrogel-microparticle composite was determined separately using
light and ascorbic acid hydrogel.
3.2.3.1 Total NO release using light
For the total NO release from hydrogel-microparticle composite using light, hydrogel
microparticles composite was placed in an amber vial and illuminated with a 470 nm LED
(VAOL-5GSBY4, Mouser electric, Mansfield, TX) at full intensity at voltage (12V). The
NO release was measured until all the NO was released from the composite.
3.2.3.2 Total NO release using ascorbic acid hydrogel system
Another method used for measuring the total NO release from the composite was using
ascorbic acid hydrogel composite. Hydrogel-microparticle composite was placed in an
amber vial with a magnetic stir bar and then ascorbic acid hydrogel composite was placed
above it. In this case too, the NO release was measured until all the NO was released from
the composite.
Both NO release experiments were performed at room temperature. The NO levels in ppb
unit were converted to moles sec-1 mg−1 unit using the NOA instrument constant that was
determined by quantitative reduction of a known quantity of nitrite. Integration of NO
release rate curves for given period was done to calculate the amount of NO released in
both experiments.
3.2.4

Statistical analysis

The statistical analysis of the data was done using MS-excel 2016. All the data were shown
as the means (±SD). Two-tailed homoscedastic student’s t-test was used to statistically
analyze the data. The p value (<0.05) was considered significant. The graphs were made
using the GraphPad Prism version 7.00 for Windows, GraphPad Software (La Jolla,
California, USA) (www.graphpad.com).
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3.3 Result
3.3.1

Microparticle Hydrogel Composite

This hydrogel-microparticle composite combining SNAP loaded PLLA microparticles
incorporated in chitosan–agarose hydrogel was designed with the aim of developing a
wound dressing with accelerating wound healing properties and prolonged NO release
period. In theory, the chitosan-agarose hydrogel can act as a hemostatic agent to accelerate
the process of wound healing and the NO release from microparticles can act antibacterial
agent to prevent infection and biofilm production. Hydrogel microparticle composites were
prepared with the method described in chapter (20). During hydrogel preparation,
microparticles are first made into microparticle suspension in 2.5 (v/v) % acetic acid
solution which is stirred for 1 h. It was done to obtain homogeneous distribution of
microparticles in hydrogel, microparticle suspension has to be homogenous without large
microparticle aggregates. Preparation of microparticle suspension in acetic acid prevents
the degradation of SNAP in the microparticles as SNAP is more stable at acidic pH. It also
helps in dissolving chitosan as it is insoluble in water. Even though SNAP loaded PLLA
microparticles do not form homogenous suspension with water easily due to large
microparticle size, they were just stirred for 1h to prevent SNAP degradation in suspension.
In this study, the hydrogel preparation was done according to protocol developed by Cao
et al. and the gel formulation for composite was chosen from the literature. The agarose
concentration was maintained at 1 (w/v) % which has shown to support the best neurite
outgrowth from chick dorsal root ganglion (DRG) (22). Hydrogels with 188 μg/mL of
chitosan have exhibited a bactericidal activity. A bactericidal activity was noticed for
hydrogels containing more than 188 μg/mL of chitosan. 1.5% (w/v) % of chitosan was
chosen in this study as it has shown to improve wound healing process and prevent bacterial
infection at wound site (21). The amount of microparticle chosen to be introduced in the
composite was 5 mg which is the same amount used for in vivo testing of microparticles.
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3.3.2

Morphology of hydrogel-microparticle composite

Visual appearance of the hydrogel-microparticle composite and control hydrogel without
microparticles is illustrated in the fig.5.1. The shape of both composite gel (microparticlehydrogel) and the control gel (only hydrogel) is regular cylinder shape which is due to the
shape of the mold in which they are prepared. Color of the composite gel is white and
translucent with visible embedded microparticles. In comparison, control hydrogel is
throughout transparent due to absence of microparticles. Microparticles are visible in the
hydrogel because of their bigger size. Majority of the microparticles have diameter in the
range of 100-300 µm, they are a little difficult to embed into the thicker walls of the gel.
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(a)

(b)

(c)

(d)

(e)

(f)

Figure 3.2 (a) and (b) shows hydrogel-microparticle composite. (c) and (d) shows blank
hydrogel without microparticles. (e) and (f) depicts the ascorbic acid chitosan-agarose
hydrogel.

3.3.3

In vitro NO release profile study of microparticles hydrogel composite

3.3.3.1 Total NO release study via Light
Total NO release from the hydrogel-microparticle(500) and hydrogel-microparticle(2500) is
shown in fig. 5.2 (a) and (b) respectively. LED Light source (VAOL-5GSBY4, Mouser
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electric, Mansfield, TX) of 470 nm was used as a trigger to initiate NO production from
hydrogel-microparticle composite. Light source had to be kept at an intensity suitable for
maximum NO release within the detection limit of nitric oxide analyzer. That is why light
source was kept at 4V during the testing. Increasing the voltage exceeded the NO detection
limit which is undesirable. The reason for this is to keeps the NO release in detection limit.
NO release profile follows the same biphasic profile as NO release profile of the SNAP
loaded microparticles.
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Figure 3.3 Light initiated total NO release from (a) Hydrogel-microparticles(500) and (b)
hydrogel-microparticles(2500)
The NO release rate of hydrogel-microparticle(2500) composite is similar to the
microparticle(2500).The comparison of light initiated total NO release rate from Hydrogelmicroparticles(500) and hydrogel-microparticles(2500) is shown in Fig. 5.3. The initial average
burst release is 46.3% ± 6.1 of total NO measured in hydrogel-microparticle(2500) while
release rate is faster in case of hydrogel-microparticle(500) composite with an initial burst
release of 69.6% ± 19.3 of total NO measured. The burst release occurs for almost 2 h.
These results are perplexing as even more sustained NO release was expected.
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Figure 3.4 comparison of light initiated total NO release rate from Hydrogelmicroparticles(500) and hydrogel-microparticles(2500)
3.3.3.2 Effect of particle size on total NO release due to light in microparticle hydrogel
composite
The amount of NO released from the hydrogel-microparticle(500) and hydrogelmicroparticle(2500) were compared using two tail t-test. The results as shown in Fig. 5.4
displayed a significant difference in total NO release between both the composite systems
(p=0.04). This can be attributed to the difference in size of microparticles which was also
seen in only microparticle system.
Compared to only microparticles, less release was observed from both composites that may
be either due to degradation of SNAP in the microparticle during hydrogel preparation or
interaction between microparticle and hydrogel which reduces NO release. However,
release from hydrogel-microparticle(500) composite was much lower than hydrogelmicroparticle(2500) composite in relation their respective microparticle NO release. Using
light as a trigger, the NO release from the hydrogel-microparticle(500) was just 25.68% ±
5.9 of total NO released from only microparticles(500). While, the NO released from the
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hydrogel-microparticle(2500) was 50.3% ± 14.5 of total released NO from microparticle(2500).
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Figure 3.5 comparison of total NO release rate from the hydrogel-microparticle(500) and
hydrogel-microparticles(2500)

3.3.4

Total NO release study via ascorbic acid hydrogel

Another hydrogel system containing ascorbic acid prepared as described in method was
used as an initiator for NO release study from the hydrogel-microparticle composite
system. In this study, shown in fig. 5.5, ascorbic acid hydrogel was placed above the
hydrogel-microparticle composite and total NO release was measured. A magnetic stirrer
was used for proper mixing. Total NO release from the hydrogel-microparticle(500) and
hydrogel-microparticle(2500) using ascorbic acid is shown in figure 5.6 (a) and (b)
respectively. Same as microparticle study, only 100mM ascorbic acid was used in study.
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NO release profile follows the same biphasic profile as NO release profile of the SNAP
loaded microparticles. However, in this study after the burst release, the slower release
period was very short.

Figure 3.6 Illustration of ascorbic acid loaded chitosan agarose hydrogel system used for
NO release study in hydrogel-microparticle composite
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Figure 3.7 Ascorbic acid initiated total NO release rate from the (a) hydrogelmicroparticle(500) and (b) hydrogel-microparticles(2500)
The comparison of ascorbic acid initiated NO release rate from the hydrogelmicroparticle(500) and hydrogel microparticles(2500) is shown in Fig. 5.7. The hydrogelmicroparticle(2500) and hydrogel-microparticle(500) composite exhibit an average burst
release of 38.6 ± 12.3 and 44.8% ± 11.4 respectively. The burst release time for hydrogelmicroparticle(2500) is again 2h but the total release time has decreased to almost 6h. In case
of hydrogel-microparticle(500) burst release is very short as well as the total release time.
The nitric oxide release analysis through ascorbic acid hydrogel showed low total NO
output. When compared to total NO output in microparticles, hydrogel-microparticle(500)
and hydrogel-microparticle(2500) displayed only 30.2% ± 12.4 and 35.4% ± 2.9 NO output in
relation to their respective microparticle counterparts. Even though more sustained NO
release was expected in this case too, the low NO release may be due to any interaction
of the hydrogel-microparticle composite with another ascorbic acid hydrogel.
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Figure 3.8 comparison of ascorbic acid initiated NO release rate from the hydrogelmicroparticle(500) and hydrogel microparticles(2500)

3.3.4.1 Effect of particle size on total NO release due to ascorbic acid hydrogel
in microparticle hydrogel composite
Similar to the previous study, the amount of NO released from the hydrogelmicroparticle(500) and hydrogel- microparticle(2500) were compared using two tail t-test. The
results as shown in in Fig. 5.8 displayed a significant difference in total NO output due to
ascorbic acid hydrogel between both the composite systems (p=0.01). Again, the
significant difference in NO release between two different hydrogel-microparticle systems
due to ascorbic acid can be attributed to the difference in size of microparticles which was
also seen in total NO release in only microparticle system and light initiated NO release in
hydrogel-microparticle composite system. Degradation of SNAP in the microparticle
during hydrogel preparation or interaction between microparticle and hydrogel can be the
reason for observed less release which reduces NO release.
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Figure 3.9 comparison of total NO release from the hydrogel-microparticle(500) and
hydrogel-microparticles(2500)
Table 4 shows the average total nitric oxide released from hydrogel-microparticle(500) and
hydrogel-microparticle(2500) by exposure to light and ascorbic acid hydrogel. The average
ratio of NO output of hydrogel-microparticle(500) through light and ascorbic acid is 1.07 ±
0.82 while average ratio of NO output of hydrogel-microparticle(2500) through light and
ascorbic acid is 1.41 ± 0.29. This shows that total NO release from both the hydrogelmicroparticle system by using both light and ascorbic acid hydrogel triggers are almost
similar.
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Table 4 comparison of average total nitric oxide release from hydrogel-microparticle(500)
and hydrogel-microparticle(2500) by exposure to light and ascorbic acid hydrogel

Composition
Hydrogel-microparticle(500)
Hydrogel-microparticle(2500)

Average total NO release ± s.d.
Exposure to light
Exposure to ascorbic acid
hydrogel
1.63 ± 0.84 x 10-8
1.71 ± 0.37 x 10-8
4.87 ± 1.70 x 10-8
3.41 ± 0.54 x 10-8

3.4 Discussion
3.4.1

Hydrogel-microparticle composite

In this study, a SNAP hydrogel-microparticle composite was designed in order to modify
drug release profile of the microparticles. Used hydrogel was prepared from chitosan and
agarose in acetic acid solution. During hydrogel preparation step microparticles were
introduced in a form of microparticle suspension. Control gel and composite gel both had
regular cylindrical shape. Small microparticles with less diameter are easily embedded in
to the microparticles, however bigger microparticles with large diameter were visible in
the hydrogel even after making them in to a suspension. Most of the microparticles are in
the range of 100-300 µm which can be the main reason for visible microparticles in
hydrogel.
Drug release test from the hydrogel-microparticle composite was done using two different
triggers for nitric oxide release. Light and ascorbic acid hydrogel were used to initiate NO
production from the SNAP loaded inside the microparticles which are embedded in the
hydrogel.
Light initiated NO release from the composite showed fast release in hydrogels embedded
with microparticle(500) whereas the NO release from the hydrogels embedded with
microparticles (2500) was almost similar to the microparticles(2500). Ascorbic acid hydrogel
system was also used in the study of NO release from the composite hydrogel. Ascorbic
acid initiated NO release from both the hydrogel microparticle composite exhibited very
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fast NO release. Like NO release study done with the light, these results were not expected
since more sustained NO release was expected. Although NO release is hard to predict due
to possible interaction between the components, hydrogel forms an extra barrier between
the NO release triggers and SNAP. Therefore, a reasonable expectation is slower release
profile in both the cases. However, hydrogels do not always necessarily delay the release
from the microparticles as seen in case of poly (lactide) (PLA) microparticles embedded in
poly (ethylene glycol) – poly (H-caprolactone) – poly (ethylene glycol) hydrogel that
exhibited slightly accelerated release (23). There can be some reasons for unexpected
behavior. First can be microparticle size. The explanation of this can be bigger size of the
microparticles. The size of microparticle(500) is pretty large which can prevent them from
fully encapsulating inside the mesh of the formed hydrogel. Every hydrogel has a certain
mesh size. If the size of the microparticles is bigger than mesh, they will be difficult to
embed and remain close to the hydrogel boundaries resulting in easy and fast release of the
drug. Another reason can be testing parameters. In the total NO release analysis of
microparticles all triggers were used, but case of in hydrogel only light and ascorbic acid
were used separately.
Apart from the rate of release, hydrogel-microparticle composite showed overall less
amount of NO release compared to their microparticle counterparts. Usually, it is taken in
to account that adding any more processing parameter can result in decrease of degradation
of the matrix or the drug. In this case, the drug i.e. SNAP is sensitive to light, any trace of
metal ions (Cu+) and ascorbic acid. Hydrogel-microparticle composite manufacturing
process could cause SNAP loss from the microparticles. There is a high possibility that
loss of SNAP occurs during the preparation of the homogenous microparticle suspension.
The degradation of SNAP in the microparticles could have occurred due to their presence
in the suspension or the thermal decomposition of SNAP microparticles when the
microparticle chitosan agarose suspension was kept in water bath at 60℃. The other reason
can be polymer-polymer interactions. In general, it is hard to predict drug release from the
microparticles, then it is obvious that it is more complicated in case of composite gels that
has different components involved. Composite gel used in this study involves three
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different polymers PLLA, chitosan and agarose. Interaction between any of these
components with each other may accelerate the degradation of the matrix and NO release.

3.5 Summary
In this study, it has been shown that NO donor SNAP encapsulated PLLA microparticles
can be embedded into thermosensitive chitosan-agarose hydrogel. These hydrogelmicroparticle composite have demonstrated to release nitric oxide on exposure to light and
ascorbic acid. The drug release rate from these composites was fast compared to the
microparticles. Based on the size of microparticles incorporated in hydrogel, the hydrogelmicroparticles(2500) composites exhibited significant difference in NO release from
hydrogel-microparticles(500). These composites can be successfully used as wound dressing
utilizing the properties of chitosan and agarose in accelerating wound healing as well as
antibacterial activity of nitric oxide.
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4 Conclusion and future propositions
Chronic wounds are a major burden to the healthcare industry. Current treatments available
are not satisfactory to treat chronic wounds due to their inability to prevent bacterial
infection and stimulate growth of healthy cells around wounded tissue. There is an urgency
to develop new methods of infection control as some bacterial strains (also known as
superbugs) continue to develop resistance against antibiotics. Therefore, there has been an
interest in exploring the role of a small molecule nitric oxide naturally produced by cells
during wound healing and development of NO delivery devices.
The main aim of this work was to develop stable polymeric systems capable of delivering
nitric oxide in a sustained and controllable manner for their potential application as wound
healing materials. There were two goals of this study: (a) synthesize and study an efficient
microparticle release system encapsulating a NO donor SNAP and, (b) to develop
hydrogel-microparticle composite material to modify the NO release profile. In this study,
SNAP was successfully encapsulated in the PLLA microparticles using solvent
evaporation water-in-oil-water double emulsion at a rotor stirring speed of 500 rpm and
2500 rpm. In this microparticle formulation, HCl was added to the PVA aqueous phase of
the emulsion to prevent SNAP degradation as it is more stable at acidic pH. The
microparticles produced at 500 rpm and 2500 rpm had particle sizes of 256 ± 11.7 µm and
207 ± 19.7 µm with an encapsulation efficiency of 35.2 ± 5.6% and 33.0 ± 1.4%
respectively. There is a significant difference in release profile between both microparticles
due to difference in microparticle size. The microparticles prepared at 500 and 2500 rpm
released an average of 6.11 ± 1.71 x 10-8 and 8.43 ± 2.92 x 10-8 of total encapsulated nitric
oxide for almost 9h and 13h respectively on exposure to light, copper and ascorbate. The
microparticles also demonstrated controlled NO release on exposure of different intensities
of light which can be used to regulate the amount of nitric oxide according to the
requirement. The microparticles had an accelerated NO release and higher burst rate which
may be due to irregularities on surface and collapsed microparticles because of air drying.
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Also, SNAP loaded hydrogel-microparticle composites were developed. The hydrogelmicroparticle composite also showed sensitivity to light and ascorbic acid and allow SNAP
decomposition and NO release on exposure to them. The hydrogel-microparticle(500) and
hydrogel- microparticle(2500) composite released an average total of 1.63 ± 0.84 x 10-8 and
4.87 ± 1.70 x 10-8 nitric oxide respectively with only light as a trigger. On the other hand,
ascorbic acid chitosan-agarose hydrogel used for release study demonstrated an average
total of 1.71 ± 0.37 x 10-8 and 3.41 ± 0.54 x 10-8 nitric oxide release from the hydrogelmicroparticle(500) and hydrogel-microparticle(2500) composite. Nitric oxide release from the
composite gel was faster compared to the only microparticles which is likely due to larger
size of microparticles or problems with the preparation of the microparticle suspension. A
significant difference in release profile between both hydrogel microparticle composite
systems was observed. The NO release from the composite for several hours may be useful
for short term applications where fast release is needed such as wound healing.
Based on these results, future work can be done to further determine if the SNAP loaded
microparticles and hydrogel-microparticle composites are effective in delivering enough
nitric oxide for inhibiting the bacterial growth. A bacterial study can provide major
evidence regarding the antibacterial activity of these microparticles and composites as in
the wound healing process antibacterial activity of NO is the most critical feature.
Additionally, it can be studied if this type of dosage (high initial NO release for shorter
time period) is effective on bacterial inhibition. Furthermore, in vitro studies such as in
endothelial, epithelial cells and in vivo studies in animals can be done after the successfully
determining the necessary dosage and surface flux necessary to impede bacterial infection
in wound healing process.
For future improvements in the development of this system, it is suggested to make various
changes to the formulation of this microparticles system to sustain nitric oxide release for
longer period. Some other polymers such as poly (lactic acid-co-glycolic acid) (PLGA) can
be used for encapsulation of nitric oxide donor using the encapsulation technique described
in this thesis. Alternatively, microparticles could be coated with the drug free polymer
(same or another) to slow down the release. Microparticles can be produced at different
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stirring rates to further determine its effect in SNAP encapsulation. It would be worth to
try encapsulating more amount of SNAP during production of microparticles to study
efficient loading of microparticles. Another type of nitric oxide donors such as SNAPcyclam developed by our lab can be used in these microparticle system as it degrades
slowly compared to SNAP (1). Copper is main metal ion responsible for the degradation
of SNAP and NO release which is studied in his research, however, activity of other metal
ions such as Fe, Zn etc. on SNAP microparticles and composites can also be studied for
NO release from these microparticles (2).
Additionally, further testing of the hydrogel-microparticle composite is advisable. There
are various published articles which have studied sustained modified drug release profiles
of microparticles embedded in the hydrogels (3). In this thesis, only preliminary nitric
oxide release test was performed from both microparticles and hydrogel-microparticle
composite. Further testing such as mechanical and stability of the composite can be
performed.
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